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ABSTRACT

The cannabinoid system consisting of exogenous and endogenous ligands as well
as dedicated receptors has been proposed to play a regulatory role in immune functions.
The exogenous cannabinoid ∆9-tetrahydrocannabinol (THC), one of the most widely
studied marijuana derivatives, has been associated with multiple anti-inflammatory
properties over the years. The majority of THC research has centered on the shift from
Th1 to Th2 responses however, the complexity of inflammation has since increased.
Recent studies have revealed that epigenome, Th cell subsets, and immunoregulatory cell
induction, are all known to impact inflammation. In the current research, we have
attempted to look holistically at the impact of THC on inflammation, specifically
addressing its effect on epigenome and regulatory cells such as myeloid derived
suppressor cells (MDSCs). In regards to epigenetic regulation, we found that THC
altered both DNA methylation profiles and microRNA (miRNA, miR) expression in
immune cells. THC treatment decreased DNA methylation of key genes, STAT3 and
arginase1 (Arg1), associated with the induction and suppressive capabilities of myeloid
derived suppressor cells (MDSCs). Furthermore, THC treatment triggered alterations in
miRNA expression in lymphocytes, decreasing the differentiation of Th1, via
overexpression of miR-29b, and Th17, via reduced miR-21 expression. Moreover, we
discovered that THC, a ligand for both CB1 and CB2 cannabinoid receptors, required a
fully functional CB1 receptor for optimal induction of MDSCs. Additionally, functional
vi

CB1 receptor was necessary for THC to inhibit the Th1 driven proinflammatory
response associated with host versus graft disease (HvGD) leading to allogenic graft
survival. In order to assess THC inhibition of inflammation, driven by Th1 and Th17, we
also used delayed type hypersensitivity (DTH). In this model, THC was able to reduce
both Th1 and Th17 associated cytokines and transcription factors. We have further
highlighted the importance of the endocannabinoid (EC) system in immunoregulation
through the therapeutic use of the endogenous cannabinoid receptor ligand 2arachidonoyl glycerol (2-AG) and detection of 2-AG during an ongoing DTH response.
The impact of endogenous and exogenous cannabinoids and the CB receptors on
expressed on immune cells on the regulation of immune response is an exciting area of
research with potential implications in the prevention and treatment of inflammatory and
autoimmune diseases. Taken together, our findings demonstrate for the first time how
cannabinoids can regulate the immune response through alterations in the epigenetic and
immunoregulatory pathways, thereby controlling inflammation driven by Th1 and Th17
cells. Our studies shed new light on how cannabinoid system can be targeted to
therapeutically prevent and treat inflammatory and autoimmune diseases.

vii

TABLE OF CONTENTS

Dedication .......................................................................................................................... iii
Acknowledgements ........................................................................................................... iv
Abstract .............................................................................................................................. vi
List of Tables .......................................................................................................................x
List of Figures .................................................................................................................... xi
Chapter I: Introduction .........................................................................................................1
1.1 The Endocannabinoid (EC) System ...................................................................1
1.2 Epigenetics and Immunity .................................................................................4
1.3 Immune Response in T Helper Cell Driven Inflammation ................................5
1.4 Rational for Using Cannabinoid Treatments .....................................................7
1.5 Statement of Hypothesis and Aims ....................................................................8
Chapter II: Δ9 Tetrahydrocannabinol-mediated Epigenetic Modifications Elicit Myeloid
Derived Suppressor Cell Activation via STAT3/S100A8 .................................................10
2.1 Introduction ......................................................................................................10
2.2 Materials and Methods .....................................................................................12
2.3 Results ..............................................................................................................18

viii

2.4 Discussion ........................................................................................................24
Chapter III: Δ9-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response via
cannabinoid receptor 1 mediated induction of MDSCs .....................................................39
3.1 Introduction ......................................................................................................39
3.2 Materials and Methods .....................................................................................41
3.3 Results ..............................................................................................................47
3.4 Discussion ........................................................................................................55
Chapter IV: Δ9-Tetrahydrocannabinol attenuates delayed type hypersensitivity via
microRNA regulation of Th1 and Th17 differentiation .....................................................69
4.1 Introduction ......................................................................................................69
4.2 Materials and Methods .....................................................................................72
4.3 Results ..............................................................................................................76
4.4 Discussion ........................................................................................................81
Chapter V: Endocannabinoid 2-arachidonyl glycerol inhibits inflammation associated
with delayed type hypersensitivity via reduced T cell response ........................................93
5.1 Introduction ......................................................................................................93
5.2 Materials and Methods .....................................................................................95
5.3 Results ..............................................................................................................99
5.4 Discussion ......................................................................................................101
Chapter VI: Summary and Conclusion ............................................................................108
References ........................................................................................................................111

ix

LIST OF TABLES
Table 2.I Primer sequences for the Msp PCR analysis of THC-induced and resident BM
MDSCs...............................................................................................................................30
Table 4.I Primer sequences for qPCR analysis of gene expression in popliteal lymph node
cells. ...................................................................................................................................85
Table 5.I Optimized MRM tuning parameters .................................................................105

x

LIST OF FIGURES
Figure 2.1 THC-induced MDSCS differ from resident BM MDSCs in subset proportion
and suppressive functionality.............................................................................................31
Figure 2.2 THC-induced MDSCs have differential expression of MDSC associated
proteins compared to resident naïve BM MDSCs ............................................................ 32
Figure 2.3 THC-induced MDSCs exhibit elevated levels of cytokines associated with
STAT3 activation .............................................................................................................. 33
Figure 2.4 THC alters the methylation profile of MDSCs................................................ 34
Figure 2.5 THC- induced MDSCs differ from resident BM MDSCs in promoter region
methylation ....................................................................................................................... 35
Figure 2.6 S100A8 protein impacts both MDSC induction and activation ...................... 36
Figure 2.7 Proposed working model for the mechanism of MDSC induction and
activation by THC ............................................................................................................. 37
Supplemental Figure 2.1 Arginase1 expression specific to peripheral MDSCs in THC
treated mice. ...................................................................................................................... 38
Figure 3.1 THC treatment ameliorates HvGD .................................................................. 62
Figure 3.2 THC treatment reduces lymphocyte activation in the recipient mice and allows
for allograft persistance..................................................................................................... 63
Figure 3.3 THC treatment induces immunosuppressive MDSCs ..................................... 64
Figure 3.4 Role of MDSCs in HvGD modulation as determined via MDSC depletion ... 65
Figure 3.5 Role of MDSCs in HvGD modulation as determined by adoptive transfer .... 66
Figure 3.6 THC works through the CB1 receptor to ameliorate THC-induced MDSCS
differ from resident BM MDSCs in subset proportion and suppressive functionality ..... 67
Figure 3.7 THC treatment significantly extends survival of allogenic skin grafts ........... 68
Figure 4.1 THC is involved in reducing lymphocyte driven inflammation associated with
delayed type hypersensitivity (DTH) ................................................................................ 86
Figure 4.2 THC treatment reduced T cell proliferation and infiltration ........................... 87
Figure 4.3 THC treatment causes regulation of proinflammatory T cell transcription
factors ................................................................................................................................ 88
Figure 4.4 Inflammation associated with DTH causes changes to micrRNA expression 89
Figure 4.5 THC treatment reverses DTH mediated microRNA dysregulation ................ 90
xi

Figure 4.6 THC treatment alters microRNA specific target gene expression .................. 91
Figure 4.7 Schematic of the role microRNA plays in mBSA induced DTH .................... 92
Figure 5.1 Lymphocyte activation both in vitro and in vivo causes dysregulation of
endocannabinoid levels ................................................................................................... 106
Figure 5.2 Endocannabinoid 2-AG reduces lymphocyte driven inflammation .............. 107

xii

CHAPTER I: INTRODUCTION

1.1 THE ENDOCANNABINOID (EC) SYSTEM
The first use of cannabis as an alternative medicine is attributed to ancient China
and Taiwan both of which used hemp seeds, derived from the Cannabis sativa or
marijuana plant, as dietary additives (1). The most well studied cannabinoid extracted
from marijuana is the aromatic terpenoid ∆9-tetrahydrocannabinol (THC) (2). Once
exogenous cannabinoids, such as THC, were discovered to act on the immune system, the
search for possible receptors began in earnest. The search for cannabinoid receptors led
to the discovery of the endogenous cannabinoid (endocannabinoid, EC) system (3). The
EC system consists of cannabinoid receptors and their ligands.
After THC was isolated and synthesized, two receptors termed cannabinoid
receptor 1 (CB1) and cannabinoid receptor 2 (CB2) were discovered, in 1990 and 1992
respectively, which could bind the exogenous cannabinoid (4); (5). While additional
receptors have been found throughout the years, which can use cannabinoids as ligands,
CB1 and CB2 remain the only dedicated CB receptors. All receptors associated with the
EC system are G-protein coupled receptors (GPR) consisting of seven transmembrane
helices, an extracellular N-terminus, and an intracellular C-terminus (3).

1

Somewhat controversial is the inclusion of the vanilloid and orphan GPR55
receptors to the EC system. The vanilloid receptor, which can be activated by voltage,
protons, and vanilloid compounds (such as capsaicin), as well as cannabinoids, is found
in the CNS and on immune cells (6); (7); (8). However, as many non-cannabinoid
molecules can act as activators for this receptor, it cannot be considered exclusively as
part of the EC system. GPR55 is present in numerous tissues, including the adrenals,
gastrointestinal tract, and central nervous system, and also affects the G13 peptide (9);
(10). The issue with including this receptor in the EC system is that while
endocannabinoids have been found to activate the GPR55 in transformed human
embryonic kidney cells (HEK293), these results are not always reproducible (10); (11).
The main cannabinoid receptors, CB1 and CB2, have been found to reside in
various organ systems with CB1 having the highest rate of expression in the central
nervous system and CB2, in the immune system (12); (13). However, CB1 receptors
have also been found in the immune system, in particular on activated T cells, and CB2
receptors have been found in the CNS as well as other peripheral tissues (13); (14).
While CB receptors interact with multiple ligands, specificity is maintained through
structural and conformation requirements. CB1 receptor binding requires 20-22 carbon
fatty acid chains, no less than three homoallylic double bonds, and at least five saturated
carbons at the end of the acyl chain (15). Additionally, amino acid disparity in binding
sites, due to single nucleotide polymorphisms, affects CB receptor affinity for individual
ligands (16), (17), (18), (19), (20).
Not long after the discovery of the cannabinoid receptors, endogenous ligands,
which act as lipid messengers derived from cellular membranes, were found (21). The
2

first EC discovered, N-arachidonyl ethanolamide (anandamide, AEA), was named
anandamide from the Sanskrit for “internal bliss” (22). Anandamide was first found in the
porcine brain in 1992 (3). In 1995, two independent groups isolated another endogenous
cannabinoid, 2-arachidonoyl glycerol (2-AG), (23); (24). Maintenance of EC levels
occurs through intercellular metabolism via the catabolic enzymes fatty acid amide
hydrolysis (FAAH) and monoacylglyceride lipase (MAGL), for AEA and 2-AG
respectively (25); (26); (27).
Endocannabinoids are synthesized locally as needed rather than being stored
within vesicles (28). The synthesis of AEA can occur in two main ways: one is through
N-arachidonoyl phosphatidylethanolaminephospholipase, which converts
phosphatidylcholine and phosphatidylethanolamine to N-arachidonoyl
phosphatidylethanolamine (NAPE), the anandamide precursor (29). The other accepted
pathway is through phospholipase C hydrolysis of NAPE and phosphoanandamide,
which is then dephosphorylated (30); (31); (32). However, 2-AG synthesis follows
different pathways one of which involves 2-arachidonate-containing phosphoinositols,
converted to diacylglycerols (DAGs), are finally hydrolyzed by DAG lipase (31); (32).
Additionally, 2-AG can be formed from arachidonic acid-containing phosphatidylcholine
via variable phospholipases and phosphatidic acid phosphatase (31). Upon synthesis
these lipid messengers, due to the hydrophobic nature of the molecules, remain
membrane bound till a high-affinity mechanism allows for cellular uptake to occur (33).
At first glance, the link between the EC system and immune regulation may
appear tenuous or limited to neuroimmune disorders inasmuch as the CB1 receptor was
initially understood to be CNS specific. However, in depth studies of the Jurkat T cell
3

line has shown that CB1 transcript expression is significantly increased, 29-fold, upon
CD3/CD28 activation compared to non-stimulated cells (34). Even non-immortalized
primary human T cells, isolated form peripheral blood, exhibit an 8-fold increase in CB1
transcript when activated (34). This is of great importance in the understanding of
inflammatory diseases as T cells are a major component of the adaptive immune system
and are direct mediators of a number of autoimmune diseases.
1.2 EPIGENETICS AND IMMUNITY
Epigenetic modifications are heritable changes to DNA which regulate gene
expression (35); (36). The emerging field of epigenomics, including histone marks, DNA
methylation, and microRNA expression, has been gaining attention as a way to fine tune
the immune response (35); (36). Histone marks, such as acetylation and methylation,
regulate gene expression through changes in chromatin remodeling altering DNA
availability (37); (38). DNA methylation blocks transcription factor binding, causing
inhibition of gene expression (39). Translation of mRNA is also regulated via microRNA
(miR) target gene binding or degradation (40).
DNA methylation causes reversible gene silencing through the transfer of methyl
groups to CpG clusters (41). DNA methylation can be inherited or created de novo by
DNA methyl transferases (DNMTs) which transfer metyhyl groups from S-adenosyl-Lmethionine (SAM) to the 5-position on cytosine residues found in CpG clusters within
the DNA sequence (42). DNMTs can be broken into two groups those that maintain
methylation patterns and those that alter methylation patterns through increased methyl
transfers. DNMT1 is considered a maintenance DNMT as it binds preferentially to
hemimethylated DNA (39). De novo metyhylation of CpG clusters occurs via the
4

DNMT3 family, 3a and 3b (41). It has been suggested that DNA methylation, at both a
local and global level, is vital to proper cellular function (43); (44). Specifically, DNA
methylation has been linked to immune function and immune cell differentiation (45);
(46); (47).
microRNA (miRNA, miR) are short strands of RNA, around 20 nucleotides long,
which originate from non-coding RNA (40). While non-coding RNA was initially
considered useless, the role of miRNA as a gene expression regulator was discovered in
the 1990’s (48). miRNA most commonly inhibits gene expression through the binding of
mRNA sequences; however miRs can also bind and degrade mRNA transcripts (40).
Each miRNA has been predicted to bind numerous targets and therefore regulate the
expression of various genes (40). An evolving role of miRNA in relation to immunity
focuses on the regulation of T helper cell lineage-defining transcription factors and
downstream targets (49); (50).
1.3 IMMUNE RESPONSE IN T HELPER CELL DRIVEN INFLAMMATION
T helper cells can differentiate into proinflammatory, anti-inflammatory, or
regulatory cells based on lineage specific signals. Classically, T cell driven inflammation
has been associated with the Th1 cell subset, and therefore elevated expression of IFN-γ,
TNF-α, IL-12, and the transcription factor Tbx21 (Tbet) (51). Additionally, IL-17
producing cells, known as the Th17 cell subset, have been associated with progression of
inflammatory disease (52). Hallmarks of Th17 cell driven inflammation include elevated
levels of IL-6, IL-17a/f, and the transcription factors TGFβ and IRF4 (51). While
proinflammatory signals are necessary to maintain T cell activation and proliferation,
immune regulatory or suppressive cell responses are also critical. Immune regulators
5

include T regulatory cells (Treg) and myeloid derived suppressor cells (MDSC), both of
which are induced by proinflammatory microenvironments (53, 54); (55); (56). MDSCs,
a subset of immature myeloid cells, which suppress T cell proliferation via L-arginine
depletion, are often induced in both acute and chronic inflammatory models (57); (58).
Host versus graft disease (HvGD, transplant rejection) is primarily a Th1 driven
inflammatory response initiated by the host against allogenic graft tissue. Acute HvGD is
associated with elevated levels of IL-2, IFN-γ, and TNF-α indicative of cytotoxic and
Th1 T cell activation (59). Interestingly, tolerance of allogenic graft cells/tissue has been
found to be dependent on T cell subset regulators such as IL-6 levels and MDSC
recruitment (59); (60). While success of allogenic transplants has increased significantly
over the years, this is primarily due to severe immune suppression. The most common
immune suppressive drugs; corticosteroids, calcineurin inhibitors, anti-proliferatives, and
mammalian target of rapamycin (mTOR) inhibitors have increased graft survival (61);
(62); (63); (64); (65). However, continued usage of these drugs causes side effects
including immunotoxicity, leukopenia, susceptibility to cancer and/or infectious disease,
and can even delay functionality of the graft (61); (66); (62); (67); (68); (63).
Type IV hypersensitivity commonly known as delayed type hypersensitivity
(DTH, contact dermatitis) is a more complex model of inflammation resulting in
combined Th1/Th17 activation (69); (52). The ability of DTH to induce both major
proinflammatory T helper subsets stems from the activation of toll like receptors (TLR2
and TLR4) (70); (71, 72). It has been shown that activation of TLR2 and TLR4 causes
secretion of IL-12 and IL-6, Th1 and Th17 differentiating cytokines respectively (70);
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(71); (72). Type IV hypersensitivity is therefore associated with elevated IFN-γ and IL17a/f expression (69); (52).
1.4 RATIONALE FOR USING CANNABINOID TREATMENTS
As mentioned earlier THC, AEA and 2-AG have all been shown to act through
the CB1 receptor. The G-proteins that CB1 receptors activate include Gi, inhibitory
proteins, which are known to modulate adenylate cyclase (73). Furthermore, the CB1
receptor upon activation has been found to increase ceramide, a bioactive lipid implicated
in cellular differentiation, proliferation, and apoptosis (74). Additionally, recent findings
show that AEA (mM) works in a CB1 dependent manner to induce myeloid derived
suppressor cells (MDSCs), a regulatory cell type which has been shown to inhibit
inflammatory responses to T cell activation (75). These data suggest that the EC system
works through the CB1 receptor to elicit an anti-inflammatory response, upon activation
of immune cells.
The anti-inflammatory properties of THC, including suppression of the antitumor
response, have been well studied (76); (77); (78); (79); (79). THC has been shown to
suppress inflammatory responses using various mechanisms such as apoptosis, altering
the cytokine milieu, and through the induction of regulatory immune cells such as Tregs.
THC exposure has been linked to cannabinoid receptor dependent apoptosis in splenic
and thymic T cells, dendritic cells (DCs), and macrophages (80); (81); (82). In addition
to apoptosis, THC can induce immunsupression by shifting the cytokine profile from
proinflammatory (Th1 or Th17) to anti-inflammatory (Th2) (76); (83); (78).
Cannabinoids have also been observed to decrease lymphocyte driven immune responses
through the activation of regulatory cells such as Tregs and MDSCs (84); (85); (86); (75).
7

Furthermore, recent findings have shown that THC treatment can also affect epigenetic
modifications including alteration of histone marks, DNA methylation profiles, and
miRNA expression (38); (87); (88).
ECs have also been found to influence the immune response. Focusing first on 2AG, it was found that its addition to anti-CD3 mAb activated T cells inhibited
proliferation, but only at low cell density (89). Additionally, in vitro incubation with 2AG was found to suppress IL-2 in activated Jurkat T cells at microMolar concentrations
as well as in primary splenocytes (90); (91). Looking at the mitogen-induced
proliferation of T cells, a dose-dependent inhibition was observed when AEA was added
to in vitro cultures (92). In another in vitro experiment, it was found that when AEA was
present at microMolar concentrations, prior to OVA stimulation, it caused decrease in
IFN-γ production in ConA-stimulated splenocytes (93). Additionally, AEA treatment has
also been shown to induce MDSCs in a CB1-dependent manner, and alter miR expression
in DTH (75); (83).
1.5 STATEMENT OF HYPOTHESIS AND AIMS
There are over 80 autoimmune and inflammatory diseases in which there is no
cure. Thus, the current treatment strategy includes use of immunosuppressive drugs that
have significant toxicity and side effects. Moreover, chronic inflammation triggers a
large number of clinical disorders including cardiovascular, neurodegenerative, cancer,
obesity and the like. Thus, scientists are working towards understanding inflammatory
pathways so that better targeted therapeutics can be developed to treat inflammation. In
this context, cannabinoid receptor-ligand system which have been discovered on immune
cells and system, offer novel approaches to regulate inflammation.
8

In the current research, we tested the central hypothesis that cannabinoids regulate
inflammation through alterations in the epigenetic pathways, including DNA methylation
and miRNA expression, leading to suppression of proinflammatory T cells and
enhancement of regulatory T cell and MDSC pathways. To this end, we assessed the
ability of THC to enact an anti-inflammatory tone in a wide array of inflammatory
disease models such as HvGD, allograft rejection, and DTH response and we noted
consistently, data supporting a role for epigenetic modifications involving DNA
methylation and miRNA expression. Additionally, we set out to prove that THC
treatment inhibits classical, Th1, as well as non-classical, Th17, T helper cell driven
inflammation, while enhancing MDSCs. Finally, using the natural ligand for the
cannabinoid receptors, 2-AG, we determined that the endocannabinoid system does play
an integral role in regulating inflammatory responses.
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CHAPTER II: Δ9 Tetrahydrocannabinol-mediated Epigenetic Modifications Elicit
Myeloid Derived Suppressor Cell Activation via STAT3/S100A8.
2.1 INTRODUCTION
Myeloid-derived suppressor cells (MDSCs), which were originally observed in
cancer models, are anti-inflammatory mediators which can be helpful or harmful
depending on the context. In cancer models MDSCs inhibit the T cell driven response
against tumors allowing for cancer growth and metastasis (94); (95). However, in
autoimmune diseases, MDSC induction is advantageous, working to reduce proliferative
T cell inflammation (54); (53); (55); (56). It is therefore necessary to understand the
mechanisms which lead to MDSC induction and activation in order to best utilize this
duality. MDSCs can be categorized, in mice, into two major subsets granulocytic
(Ly6G+Ly6C+GR1+CD11b+) or monocytic (Ly6G-Ly6C+GR1+CD11b+) (96).
Additionally, MDSCs are defined by their ability to suppress T cell responses including
proliferation (97); (98). The classic mechanism for MDSC suppression of T cell
proliferation is L-arginine metabolism via either cytokine-induced nitric oxide synthases
(iNOS or NOS2) or arginase1 (Arg1) (99).
As gene regulation is integral for cell function and development, interest in
dynamic epigenetic modifications has become paramount. DNA methylation, one of the
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most common forms of epigenetic regulation, controls gene expression by
blocking transcription machinery causing reversible gene silencing . DNA methylation,
both de novo and inherited, is dependent on DNA methyltransferases (DNMTs) (41).
DNMTs transfer methyl groups from SAM (S-adenosyl-L-methionine) to the 5-position
on cytosine residue found in CpG clusters within the DNA sequence (42). DNMT1, binds
preferentially to hemimethylated DNA and is considered to be the maintenance DNMT,
and the DNMT3 family, 3a and 3b, is deemed necessary for de novo methylation (41).
Altered DNMT profiles are often seen in cancer patients suggesting that global
methylation is vital to proper cellular function though no direct association between
altered methylation profiles and MDSC induction has been highlighted in these studies
(43); (44). Furthermore, DNA methylation has been linked to not only immune function,
but also to immune cell differentiation (45); (46); (47); (100); (101); (102). Interestingly,
MDSCs are not a terminally differentiated immune cell population. Rather MDSCs are
considered a heterogeneous mixture of immature myeloid-origin cells which can
differentiate into DCs or macrophages (103). It is the plasticity of immature cells which
suggests that DNA methylation could be playing a role in both MDSC maintenance and
activation. However, there is only one recent study indicating that HDAC11 may play a
role as an epigenetic regulator in MDSC expansion and function (104).
Δ9-Tetrahydrocannabinol (THC), an exogenous cannabinoid derived from the
Cannabis sativa plant, has long been known to act as an anti-inflammatory agent as well
as suppress antitumor immune response (76); (77); (78); (79); (84). The
immunosuppressive properties of THC, in cancer models, were shown to be, in part, due
to the induction of Th2 anti-inflammatory cytokines (IL-4 and IL-10) and correlating
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decrease of Th1 pro-inflammatory cytokines (IL-2 and IFN-γ) (76); (78). THC has also
been shown to induce T regulatory cells (Tregs) (84); (85). Additionally, recent studies
from our laboratory have suggested that administration of THC into mice can trigger
large numbers of immunosuppressive MDSCs (86).
While it has been shown that THC can alter cytokines and transcription factors
linked to MDSC differentiation or homing, its role in MDSC expansion and activation
has not been clearly elucidated (86); (87); (75). Furthermore, the role of epigenetic
pathways in the induction of MDSCs by THC has not been determined. In the current
study, we investigated the effect of THC on methylation of several genes involved in the
differentiation and activation of MDSCs, and our data demonstrate epigenetic regulation
of several of the critical molecules involved in MDSC activation and functions including
Arg1 and STAT3.
2.2 MATERIALS AND METHODS
MiceFemale C57BL/6 (wild-type, BL6) mice, aged 6-8 weeks and at an average weight of 20
g, were obtained from the National Cancer Institute (Frederick, MD). All mice were
housed in pathogen-free conditions and allowed ad libitum access to filtered water and
Teklad rodent diet 8604 (normal chow) at the Animal Research Facility located at the
University of South Carolina School of Medicine. All experiments were conducted under
an approved Institutional Animal Care and Use Committee animal protocol.
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Treatment with THCTHC (NIDA-NIH) dissolved in ethanol was diluted in 1xPBS to a concentration of 20
mg/kg. THC was administered intraperitoneally (i.p.) into naïve mice. For depletion of
S100A8, mice were given an i.p. injection of antiS100A8 (0.01 mg/mouse 8H150) 1 hour
after THC treatment.
MDSC IsolationSixteen hours after THC injection, mice were euthanized and the peritoneal exudate
collected, three washes of 5 mL of ice cold 1xPBS were injected into the peritoneal
cavity and after five minutes, with agitation, collected. The cells were resuspended in 1
mL then treated with Fc block for 10 minutes and labeled with PE conjugated anti-Gr1
Abs. The +EasySep positive PE selection kit procedure was followed to isolate Gr1
positive cells, as described (105). After isolation, cells were labeled with FITCconjugated anti-CD11b and assessed for purity using flow cytometeric analysis, gating on
live cells. To isolate Ly6G and Ly6C positive cells +EasySep positive PE and FITC
selection kits were used respectively. Purity of the MDSC subset populations was
assessed by using duel staining with Alexa Fluor 647-conjugated anti-CD11b.
Monoclonal Antibodies, Reagents, and Flow CytometerAntibodies used for flow cytometric analysis (BioLegend) include: Fc block (93), PE
conjugated anti-Gr1 (RB6-8C5), FITC conjugated anti-CD11b (M1/70), PE conjugated
anti-Ly6G (1A8), FitC conjugated anti-Ly6C (HK1.4), and Alexa Fluor 647 conjugated
anti-CD11b (ICRF44). Briefly, peritoneal lavage cells (106 cells) from BL/6 mice were
incubated with Fc receptor antibodies (5-10 minutes) and incubated with conjugated
13

antibodies (20-30 minutes at 4°C). Next, cells were washed twice with 1xPBS/2% fetal
bovine serum buffer. The stained cells were then assessed by flow cytometer (FC500;
Beckman Coulter) and the resulting data analyzed by Cytomics CXP software (Beckman
Coulter). Two-color flow cytometric analysis was completed for assessing presence of
MDSCs in the bone marrow and peritoneal exudates. Three-color flow cytometric
analysis was used to profile the MDSC subsets.
MeDIP-seqPurified genomic DNA was treated with dsDNA Shearase (Zymo Research, Irvine, CA).
DNA fragments with size from 200bp to 400 bp were purified to construct sequencing
library using Illumina Chip-seq library preparation kit. dsDNA was then denatured and
immunoprecipitated with anti 5-methylcytosine antibody using a MeDIP kit from
Diagenode (Denville, NJ). Precipitated DNA was purified and sequenced by HiSeq2500
(Tufts Genomic Core, Boston, MA). The sample before immunoprecipitation was also
sequenced as input control.
MeDIP data AnalysisMeDIP-seq libraries were sequenced with single-end reads of 50bp. Raw sequencing
reads were mapped to mouse genome build mm9 using Bowtie software by allowing two
mismatches in the read (106). The mapped reads were then filtered and only uniquely
mapped reads were used for the downstream analysis. Mapped reads were analyzed with
MEDIPS software (107), and visualized in IGB genome browser (http://bioviz.org/igb).
The location of 3kb upstream and downstream of transcriptional start site (TSS) was
generated using UCSC table browser. The DNA methylation signal of all genes within
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this region was extracted. The correlations of overall DNA methylation across the whole
genome and near the TSS site (3kb up and down stream) were analyzed by CEAS
software (108).
Methylation specific (Msp) PCRGenomic DNA was isolated using the DNeasy kit (Qiagen) following the manufacture’s
protocol. Bisulfite conversion of CpG islands was completed using the Epitect Bisulfite
kit (Qiagen). Msp PCR was run with PreMix F (Epicentre) and iTaq DNA polymerase
(BioRad). Samples were assessed for expression of DNMT3a (Forward5CAGCACCATTCCTGGTCATGCAAA3; Reverse5TCAAGGTTTCCTGTCTGGTAGGCA3), and DNMT3b (Forward5GCACAACCAATGACTCTGCTGCTT3; Reverse5AGGACAAACAGCGGTCTTCCAGAT3) with an annealing temperature of 60°C.
Additionally methylated (M) and un-methylated (UM) DNA primers were used for
Arginase1, NOS2, and STAT3 (Table 2.I). Methylation index ([(M)/(M+UM)]*100) was
used to assess DNA methylation. Universal methylated mouse DNA standard (Millipore
S8000) was used as a control with all primers. Primers were generated using the Methyl
Primer Express v1.0 software, and synthesized from IDT DNA technologies.
Effect of MDSCs on T cell proliferationTo study the ability of MDSCs to suppress T cell proliferation, we used the following
assay as described (75). Concanavalin A (ConA) activated (2.5 μg/mL) spleen cells,
from naïve BL6 mice were cultured in triplicate (0.2 mL/well in a round bottom 96 well
plate) with Mitomycin C inactivated MDSCs for 38-40 hours. Ratio of MDSCs to T cells
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was 1:25 (Fig. 2.1 B only) or 1:2. Sixteen hours before collection and analysis, [3H]
thymidine (2 µCi/well) was added to the cell cultures. [3H] thymidine incorporation was
measured using a liquid scintillation counter (MicroBeta Trilux).
Western Blot AnalysisProtein was isolated from purified MDSCs using radioimmunoprecipitation (RIPA) lysis
buffer (Santa Cruz), as described (109). Five or 10 micrograms of protein was loaded
and ran on a polyacrylamide gel (12%) at 60 V for 2.5 hours. Protein was then
transferred to nitrocellulose at 100 V for 1 hour. Protein transfer was confirmed using 3
mL of Ponceau S staining solution. Nitrocellulose was then blocked in 5% nonfat dry
milk in TBS. Nitrocellulose was then probed with antibodies to S100A8 (Calgranulin A
[M-19] 1:2000), S100A9 (Calgranulin B [M-19] 1:1000), Arginase1 (V-20 1:1000),
NOS2 (iNOS [M-19] 1:500), STAT3 (C-20 1:200), P-STA (9E12 1:200). HRP
conjugated secondary antibodies were used at either 1:1000 or 1:2000 dilutions
depending on the secondary required. For control protein bands γ-tubulin (Poly6209) or
β-actin (Poly6221) were used at a dilution of 1:1000. ECL substrate (Thermo) was added
for 1 minute, exposure time varied.
ImageJDensitometry was performed on scanned western blot images as well as PCR gels using
the ImageJ gel analysis tool (110). Scanned blots and gels were assessed for absolute
density (AD), as determined by area under the curve, of each experimental and control
band. Relative density (RD), for western blots, was determined by dividing the
experimental band AD by the control band AD for both the protein of interest and a
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structural protein. The normalized density ratio (NDR) was then calculated by dividing
the protein of interest RD by the structural protein RD.
Cytokine Analysis in Cell Culture SupernatantsELISA MAX sandwich enzyme-linked immunosorbent assay (ELISA) kits (BioLegend)
were used to assess the level of IL-6, IL-10, and IFN-γ cytokines. Sandwich ELISA kits
(MyBioSource) were used to assess S100A8 and S100A9 levels. Isolated MDSCs from
the bone marrow or peritoneal cavity (2.5x106 cells/mL) from naïve or THC treated mice
were cultured in 0.2 mL aliquots in 96-well round bottom tissue culture plates for 16-20
hours. Cytokine production was quantified from cell supernatants (stored at -20°C).
Absorbance was measured at 450 nm using a Victor2 1420 Multilable counter (Wallac).
qPCRTotal RNA was isolated and purified using miRNeasy kit (Qiagen), following
manufacturer’s procedure. iScript cDNA synthesis kit (BioRad) was used according to
manufacturer’s specifications to reverse transcribe cDNA. qPCR was performed using
Sso Advanced SYBR Green (BioRad) on a CFX Connect (BioRad). Samples were
assessed for expression of βactin (Forward-5GGCTGTATTCCCCTCCATCG3; Reverse5CCAGTTGGTAACAATGCCATGT3), IL-6 (Forward5CAACGATGATGCACTTGCAGA3; Reverse-5GGTACTCCAGAAGACCAGAGG3),
and IL-10 (Forward-5GCTCTTACTGACTGGCATGAG3; Reverse5CGCAGCTCTAGGAGCATGTG3). Primers were synthesized from IDT DNA
technologies with annealing temperatures of 60°C.
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Cell Culture with conditioned media or recombinant S100A8 proteinIsolated MDSCs were plated with ConA activated splenocytes at a ratio of 1:2
(MDSC:ConA splenocytes). Conditioned media was made by incubating isolated THCinduced MDSCs with phorbol 12-myristate 13-acetate (PMA) and calcium ionophore
ionomycin (50 ng/mL and 10 μg/mL respectively) for five hours. Lyophilized S100A8
protein (MyBioSource mS100A8) was reconstituted in complete RPMI media (1% v/v
penicillin/streptomycin, 1% v/v HEPES buffer, 10% v/v heat inactivated FBS, and
0.0002% v/v 2-mercaptoethanol). 2,000 ng of mS100A8 was added at 0 and 24 hours to
cell culture wells.
Statistical AnalysisData are shown as mean ± S.E.M. Student’s t Test was used to compare data between
two groups. One-way ANOVA with Tukey post-hoc test was used to compare three or
more groups. Experimental groups were compared to controls, p < 0.05 was considered
significant.
2.3 RESULTS
T cell suppression is increased in THC-induced MDSCs.
The largest accumulation of resident MDSCs is located in the bone marrow (BM)
(99). It has been shown that MDSCs migrate from this repository to sites of
inflammation by following chemokine/cytokine signals (99). Our lab has shown that
MDSCs will also migrate to the peritoneal cavity after a single THC injection (i.p.) (86).
Knowing that the peripheral MDSCs are considered active, and therefore T cell
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suppressive, we first determined if any differences existed between the resident BM
MDSCs and the THC-induced MDSCs found in the peritoneal cavity. As such, naive
C57BL/6 (wild-type, BL6) mice were given a single i.p. injection of THC to cause
massive induction of MDSC to the peritoneal cavity, as earlier described (86). Sixteen
hours after THC treatment, peritoneal lavage was used to collect peripheral THC-induced
MDSCs. Resident BM MDSCs from naive BL6 mice were used as controls. MDSCs
were purified (>95%) using positive selection magnetic beads. Flow cytometry was used
to determine if any differences in MDSC and MDSCs subset populations existed. The
naïve BM showed ~51% of Gr1+CD11b+ cells when compared to THC-induced
peritoneal cells which contained ~83% Gr1+CD11b+ cells (Fig. 2.1A). Next, we sorted
the Gr1+CD11b+ cells and stained them further for Ly6G and Ly6C to measure
granulocytic (Ly6G+Ly6C+Gr1+CD11b+) and monocytic (Ly6G-Ly6C+Gr1+CD11b)
MDSC subset proportions (Fig. 2.1D). In order to demonstrate that the THC-induced
Gr1+CD11b+ cells were in fact T cell suppressive, we tested the levels of INF-γ secretion
which decrease significantly upon addition of THC-induced MDSCs to activated T cells
(Fig. 2.1B). We next assessed the suppressive capabilities of THC-induced MDSCs in
comparison to resident BM MDSCs. We found that THC-induced MDSCs were
significantly more suppressive of concanavalin A (ConA)-activated splenic T cells than
the resident BM MDSCs (Fig. 2.1C). With literature suggesting that MDSC subsets can
have differing levels of suppression we compared independently isolated Gr1+, Ly6G+,
or Ly6C+ MDSC subsets, Ly6C+ subsets were isolated after positive selection of Ly6G+
cells using concurrent PE and FITC positive selection for Ly6G and Ly6C respectively
(111); (112). The individually isolated pure MDSC subpopulations were then treated with
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Mitomycin C and added to ConA activated spleen cells at MDSC to spleen cell ratio of
1:2, to study the ability of MDSCs to inhibit T cell proliferation (Fig. 2.1E). In all three
isolation conditions, Gr1+, Ly6G+, or Ly6C+, THC-induced MDSCs showed
significantly more suppression of T cell proliferation than resident BM MDSCs (Fig.
2.1E).
THC-induced MDSCs exhibit differential expression of functional proteins.
To explain how THC-induced MDSCs exhibited increased suppressive
capabilities compared to resident BM MDSCs, we next looked at the expression of
functional proteins. MDSCs ability to suppress T cell proliferation has been linked to
elevated expression of L-arginine metabolizers Arg1 or NOS2 (113). The expression of
Arg1 was greatly increased in THC-induced MDSCs compared to resident BM MDSCs
(Fig. 2.2A). In order to ensure that Arg1 expression was specific to activated MDSCs,
we looked at BM and splenic MDSCs from naïve mice as well as BM, splenic, and
peritoneal MDSCs from THC-treated mice. We found no expression of Arg1 in naïve or
BM resident MDSCs though peripheral MDSCs in THC-treated mice did exhibit Arg1
expression (Supp. Fig. 2.1A). However, NOS2 expression was reduced in THC-induced
MDSCs isolated from the peritoneal cavity compared to naïve resident BM MDSCs (Fig.
2.2B). We also looked at the expression of the S100 proteins A8 and A9 due to the fact
that while cancer studies have determined that secretion of S100A8 and S100A9 are
associated with tumor induced MDSCs, no one has linked THC-mediated induction of
MDSCs to the expression of these S100 proteins (114). Elevated levels of S100A8, but
not S100A9, were observed in THC-induced MDSCs when compared to BM MDSCs
(Fig. 2.2 C&D respectively). Because STAT3 plays a critical role in MDSC expansion,
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activation and function we investigated the expression of phosphorylated STAT3 (PSTAT3) (115); (116); (117). Interestingly, THC-induced MDSCs showed an increased
expression of P-STAT3/STAT3, when compared to resident BM MDSCs (Fig. 2.2E).
STAT3 associated cytokines are upregulated in THC-induced MDSCs.
It has recently been shown that Arg1 and S100A8 are downstream targets of
STAT3 (118); (119); (87). As such, we looked at the spontaneous secretion of IL-10 and
IL-6, known STAT3 activating cytokines, from MDSCs cultured overnight after
isolation. Spontaneous secretion of IL-10 was low from both MDSC populations.
However, THC-induced MDSCs secreted significantly more IL-10 than did resident BM
MDSCs (Fig. 2.3A). This correlated with elevated expression of IL-10 message in THCinduced MDSCs (Fig. 2.3C). Spontaneous IL-6 secretion as well as the transcript was
expressed at higher levels in THC-induced MDSCs when compared to resident BM
MDSCs (Fig. 3B). This trend was supported by significantly increased IL-6 message in
THC-induced MDSCs (Fig. 2.3D).
THC treatment increases S100A8 secretion.
Because STAT3 can regulate S100 proteins (119), we next determined the levels
of S100 proteins A8 and A9. THC-induced MDSCs showed significantly increased
S100A8, but not S100A9, secretion when compared to resident BM MDSCs (Fig. 2.3
E&F respectively). Also, we found that injection of THC systemically increased S100A8
levels when compared to naïve mice (Fig. 2.3G).
THC administration alters the methylation profile in MDSCs due to decreased DNA
methyltransferases.
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We next determined if THC induces MDSCs through epigenetic regulation. To
that end, we first determined if THC could affect methylation by studying global changes
in genomic DNA methylation patterns. We found that while overall methylation was
unaffected by THC treatment, using CEAS software for correlational analysis, the
methylation at promoter regions was altered when resident BM and THC-induced
MDSCs were compared (Fig. 2.4 A&B respectively). Knowing that methylation changes
could occur due to differential expression of DNA methyltransferases (DNMTs),
specifically DNMT3a and DNMT3b, which are responsible for de novo methylation, both
resident BM and THC-induced MDSCs were assessed for DNMT methylation and
mRNA expression (120); (121). The methylation at the promoter region for both
DNMT3a and DNMT3b was increased in THC-induced MDSCs (Fig. 2.4C).
Additionally, THC-induced MDSCs had significantly reduced expression of DNTM3a
and DNMT3b compared to resident BM MDSCs (Fig. 2.4D).
THC decreases the methylation of key MDSC functional genes.
We next investigated if the increase in Arg1, NOS2, and STAT3 seen in THCinduced MDSCs resulted from alterations in the methylation of these key genes
associated with MDSC activation and function. Using Methyl Primer Express v1.0
software, individual gene methylation primers were developed for key genes associated
with the suppressive function of MDSCs (Table 2.I). Furthermore, universally
methylated mouse DNA (Methylated Standard-Millipore) was used as a baseline for
comparisons between resident BM and THC-induced MDSC methylation. Using (CEAS
software) we observed that promoter region methylation was decreased at Arg1 and
STAT3 in THC-induced MDSCs (Fig. 2.5 A&B respectively). To support the findings
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from the genomic DNA methylation analysis we used methylation specific PCR (Msp
PCR). The methylation index showed that THC-induced MDSCs had deceased levels of
methylation at Arg1 and STAT3, but not at iNOS, compared to naïve resident BM
MDSCs (Fig. 2.5C). Methylation of the S100 proteins, S100A8 and S100A9, was not
determined as there were no CpG islands found in the promoter regions of these genes.
Together, these data demonstrated that THC induces immunosuppressive MDSCs
through hypomethylation of critical genes that regulate MDSC functions.
S100A8 is important in maintaining a suppressive peripheral MDSC population.
In order to further elucidate the role S100A8 was playing in MDSC functionality,
we first created a conditioned medium (CM). The conditioned medium contained both
STAT3 activating cytokines, which could enhance Arg1 production, and soluble S100A8.
CM was created by incubating THC-induced MDSCs in the presence of PMA (50
ng/mL) and calcium ionophore (10 μg/mL). Resident BM MDSCs, were then plated with
or without CM, and ConA-activated splenocytes. Resident BM MDSCs caused just over
25% suppression of T cell proliferation in response to ConA compared to THC-induced
MDSCs which caused 50% suppression (Fig. 2.6A). However, resident BM MDSCs in
CM had significantly increased suppressive capabilities, reducing T cell proliferation by
nearly 70%, compared to BM MDSCs without CM (Fig. 2.6A).
To further determine the role of S100A8 in vivo, we treated THC injected mice
with a single dose of S100A8 antibody (8H150). The mice were then assessed for MDSC
induction in the peritoneal cavity over 16 hours, via flow cytometric analysis of
Gr1+CD11b+ cells. S100A8 Ab caused significant decrease in MDSC accumulation in
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the peritoneal cavity at the 16 hour time point (Fig. 2.6B). Furthermore, looking at
MDSC subsets, we found that upon blocking S100A8, significantly fewer granulocytic
MDSCs were induced by THC, while no significant reduction was seen in monocytic
MDSCs (Fig. 2.6 C&D respectively). Additionally, to ascertain the role of S100A8 in
MDSC-induced suppression of T cell proliferation, recombinant protein (mS100A8) was
added to plated resident BM MDSCs in the presence of ConA activated splenocytes. A
significant increase in suppression was seen in resident BM MDSCs treated in vitro with
mS100A8 compared to untreated resident BM MDSCs (Fig. 2.6E). Furthermore,
mS100A8-treated resident BM MDSCs were able to suppress T cell proliferation to
similar level as THC-induced MDSCs (Fig. 2.7C).
2.4 DISCUSSION
The mechanisms through which THC mediates immunosuppression include
apoptosis, induction of T regulatory cells (Tregs), and the induction of a switch from Th1
to Th2 phenotype (80); (78); (77). Recently, our laboratory made an exciting finding that
THC can induce massive numbers of MDSCs in vivo via activation of accessory immune
cells such as mast cells (86); (75). MDSCs are a heterogeneous and immature cell
population with an innate plasticity. Recently studies have highlighted this plasticity by
showing that MDSC subsets can induce either TH17 or iTreg cells (122). It has also been
found that MDSCs, which are generally considered beneficial in the tumor
microenvironment, secrete soluble factors such as nitrous oxide, which can induce
apoptosis in cancer cells (123). Together these findings highlight the need to understand
what factors are associated with MDSC plasticity and it is likely that epigenetic
modulation may be one of the contributing factors. As such, the focus of the current
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study was to further elucidate the mechanisms through which THC induces and maintains
a peripheral population of highly immunosuppressive MDSCs. Recently, it has been
shown that THC treatment can alter gene specific methylation patterns in lymphocytes
(38). Consequently we set out to determine the role of altered DNA methylation in the
context of THC driven recruitment of MDSCs.
Research showing the involvement of THC in epigenetic modifications is limited.
However, there is evidence suggesting that THC ingested through marijuana abuse can
elicit both indirect and direct effects on gene expression (124); (125); (126); (127); (128);
(87). Additionally, studies using SIV-infected (simian immunodeficiency virus) animals
treated with THC found that up to 50% of all gene expression alterations were due to
differential DNA methylation patterns (129). Furthermore, a CB1-dependent link with
cannabinoid treatment was discovered in the regulation of keratinocyte differentiation by
inducing DNA methylation (130). Such findings support the role of CB1 receptor
agonists, such as THC, in altering DNMT activity resulting in changes in genomic DNA
methylation patterns as seen in the current study.
Alteration of DNMT expression correlates directly with changes to gene loci
specific DNA methylation pattern (131). Specifically, the changes in the methylation
profile for transcription factors associated with MDSC activation or function, such as
STAT3, was of paramount interest to us as elevated expression of STAT3 has been tied
to increased MDSC-mediated immunosuppression (115); (116); (132); (87). We found
that STAT3 levels were significantly increased in THC-induced MDSCs. It has been
shown that that STAT3 activation, via IL-6 or G-CSF, is necessary for the expansion of
functional MDSCs in part due to regulation of NADH oxidase (133). Consistent with
25

this, we also noted significant increase in IL-6 in THC-induced MDSCs. Additionally, it
has been shown that the highly suppressive nature of activated MDSCs, via Arg1
expression, is STAT3 dependent (117). With STAT3 playing such an integral role in
MDSC functionality, the differential expression we observed between resident BM and
THC-induced MDSCs suggested that resident MDSCs may exist in a naïve or inactivated
state.
One of the hallmarks of MDSC function is their ability to suppress T cell
proliferation. MDSCs have been shown to inhibit T cell activation and proliferation via
L-arginine metabolism, oxidative stress, Treg expansion, and cysteine depletion (134);
(135); (58); (136); (137). Previously we showed that that THC-induced MDSCs have
elevated levels of Arg1 expression thereby causing the suppression of T cell proliferation
through L-arginine depletion (86). In the current study we also noted that THC-induced
MDSCs had higher levels of Arg1 when compared to resident BM MDSCs.
Furthermore, THC treatment has been associated with, a cannabinoid receptor dependent,
loss of NOS2 activation due to cAMP signal inhibition (138); (139). This may explain
why in the current study, why THC-induced MDSC did not exhibit an increase in NOS2.
Additionally, the S100 proteins, S100A8 and S100A9, have been linked to MDSC
expansion via the RAGE receptor, in cancer models (114). In conjunction with reported
findings, the elevated expression of Arg1 and S100A8 we observed in the current study
strengthen our claim that a single THC injection generates primed, or activated,
peripheral MDSCs rather than just recruiting inactivated BM MDSCs to the periphery.
Although S100A8/A9 has been associated with MAPK and NF-κB signaling
pathways, these S100 proteins can also be linked to the JAK/STAT pathway (140). For
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instance, S100A8 has been associated with STAT3 activating cytokines including IL-10,
in alveolar macrophages, and IL-6 induction, in PBMCs, creating an indirect association
with the JAK/STAT signal pathway that we also observed in MDSCs (141); (142). More
directly, P-STAT3 is known to have binding sites in the promoter region of S100A8
(119). This positive feedback interaction between STAT3 and S100A8 suggests that the
S100 protein may play a vital role in MDSC function.
Hematopoietic progenitor cells (HPCs) maintain detectable levels of S100A8, for
up to one week in culture, even upon differentiation at which point S100A9 expression is
lost (119). The role that S100A8 plays in MDSC function, however, has not been
reported. It has been shown that S100A8 is involved in granulocyte chemotaxis, and that
S100A8/A9 secretion allows for MDSC accumulation (143); (114). A study by
Hiroshima et al. observed a correlation between elevated S100A8 and Arg1 transcript
levels, in alveolar macrophages (141). This finding supports our claim that increased
S100A8 expression impacts MDSC function as an anti-inflammatory molecule similar to
IL-10 (144); (145); (141); (146). TLR activation can also be positively influenced by the
S100A8 protein (147). The current study, to the best of our knowledge, is the first one to
report that elevated S100A8 levels in MDSCs regulate increased Arg1-driven T cell
suppression.
A connection between increased S100A9 expression and the accumulation of
tumor associated MDSCs, has been reported (119). Cheng et al. determined that CT-26,
a tumor-cell conditioned media, was able to increase S100A9 expression, in vitro, in
HPCs which correlated with a loss of DC differentiation (119). Additionally, Cheng et
al. were able to show that the MDSCs accumulated via S100A9 overexpression were, in
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fact, T cell suppressive (119). While inflammation has been shown to induce MDSC
recruitment, THC treatment recruits active MDSCs without pro-inflammatory signals
(86). Moreover, our studies showed that S100A9 was not induced by THC.
The ability of THC to alter gene expression via the upregulation of key
microRNA has also been studied. A single THC treatment was found to induce miR-690
overexpression in conjunction with decreased CCAAT/enhancer binding protein
(C/EBPα), a transcription factor associated with myeloid cell differentiation, in peripheral
MDSCs (87). Specifically, over expression of C/EBPα, alone, was sufficient to increase
the expression of the S100A9 protein, which is known to decrease in mature
differentiated cells (148). As such it has been suggested that the attenuation of C/EBPα
could play a role in maintaining an immature, and therefore functional, population of
MDSCs upon THC induction (87).

THC causing a reduction of C/EBPα levels, and

therefore decreasing S100A9 expression, strengthens our claim that a S100A8 driven
mechanism for THC-induced MDSC activation plays a critical role.
The mechanism of MDSC activation is one that remains elusive due the variety of
environmental factors that are known to impact the generation, maintenance, and function
of these regulatory cells. The current study attempted to highlight a mechanism by which
THC caused the induction and activation of primed peripheral MDSCs, depicted in Fig.
2.7. After THC treatment, there is decreased methylation of STAT3 leading to an
upregulation of the transcription factor, as well as STAT3 activating cytokines (IL-10 and
IL-6), which together leads to increased P-STAT3. While low levels of IL-10 were
secreted by THC-induced MDSCs, the ability of THC to activate additional IL-10
secreting cells such as Tregs further supports that THC plays a role in STAT3 activation
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(88). P-STAT3, binds to the promoter region of S100A8 and Arg1, thereby increasing
the expression of these proteins. Additionally, upon overexpression of S100A8 and
Arg1, MDSCs became highly immunosuppressive. To the best of our knowledge this
report is the first one to identify gene specific methylation profile of MDSCs following
THC treatment, and how such epigenetic changes regulate the anti-inflammatory
properties of MDSCs involving STAT3/S100A8 positive feedback loop.
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Table 2.I. Primer sequences for the Msp PCR analysis of THC-induced and
resident BM MDSCs.
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Figure 2.1: THC-induced MDSCS differ from resident BM MDSCs in subset
proportion and suppressive functionality.
MDSCs were isolated from peritoneal exudates, at 16 hours after THC injection, and
naïve BM using positive selection magnetic beads for αGr1, αLy6G, or αLy6C. MDSCs
were Mitomycin C treated prior to plating with BL6 spleen cells activated with ConA
(MDSC:T cell ratios 1:25 and 1:2). IFN-γ was assessed, in cell supernatants using
sandwich ELISA kits (Biolegend) after co-culture. Proliferation of spleen cells was
assessed 40 hours after stimulation using [3H] thymidine (co-cultured for 16 hrs). A)
Flow cytometric analysis for MDSC proportion (dot plots gated only on live cells),
double stained for GR1+CD11b+ cells in naïve BM (left panel) and THC treated
peritoneal exudate (right panel). B) Levels of IFN-γ secreted by activated T cells with
and without MDSC co-culture. C) Ability of MDSCs to suppress proliferation of T cells.
MDSCs from naïve BM, or THC-treated peritoneal exudate MDSCs were co-cultured
with ConA activated splenic T-cells. D) Flow cytometric analysis of MDSCs from naïve
BM (left panel), or THC-treated peritoneal exudate (right panel) MDSCs following triplestaining with CD11b+, Ly6G+, and Ly6C+ cells (dot plots gated on CD11b positive
cells). E) Suppression of T cell proliferation by Gr1+, Ly6G+, Ly6C+ cells isolated from
naïve BM and THC-treated peritoneal exudate co-cultured with ConA activated splenic
T-cells. Representative data from replicate experiments (mean±S.E.M) * p < 0.05, ** p <
0.01, *** p < 0.005, **** p< 0.0001 ANOVA/Tukey.
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Figure 2.2: THC-induced MDSCs have differential expression of MDSC associated
proteins compared to resident naïve BM MDSCs.
Western blot followed by densitometric analysis via ImageJ with beta actin or gamma
tubulin used for normalization. MDSC-associated proteins including, A) Arginase1, B)
NOS2, C) S100A8, D) S100A9, and E) STAT3 (P-STAT3), in MDSCs derived from
naïve resident BM and THC-induced peritoneal exudate. Representative data from
triplicate experiments (mean±S.E.M) * p < 0.05, ** p < 0.01, *** p < 0.005, **** p<
0.0001.
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Figure 2.3: THC-induced MDSCs exhibit elevated levels of cytokines associated with
STAT3 activation.
THC-induced MDSCs and resident naïve BM MDSCs were cultured overnight and cell
supernatants collected for cytokine analysis using sandwich ELISA kits: A) IL-10, B) IL6. cDNA was isolated from MDSCs for real time (q) PCR analysis: C) IL-10 mRNA, D)
IL-6 mRNA. Spontaneous secretion from THC-induced and resident naïve BM MDSC
culture supernatants: E) S100A8 F) S100A9. Serum from THC-treated or naïve mice
were analyzed for S100: G) S100A8 levels. Representative data from replicate
experiments (mean±S.E.M) * p < 0.05, ** p < 0.01, *** p < 0.005, **** p< 0.0001
Student’s T-Test.
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Figure 2.4: THC alters the methylation profile of MDSCs.
Genomic DNA from THC-induced MDSCs (n=5 mice) and naïve resident BM MDSCs
(n=5 mice) was assessed for genomic methylation via MeDIP-seq. A) Correlations of
genome-wide DNA methylation signal (CEAS software) in THC-induced and resident
BM MDSCs. B) Correlations of DNA methylation within 3kb up and down stream of
transcriptional start site (TSS) in THC-induced and resident BM MDSCs. C) DNA
methylation near the TSS of DNMT3a and 3B (upper and lower panels respectively). D)
PCR for DNMT3a and 3b message in THC-induced and resident BM MDSCs.
Representative data from replicate experiments.
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Figure 2.5: THC- induced MDSCs differ from resident BM MDSCs in promoter
region methylation.
Bisulfite converted genomic DNA was assessed for promoter region associated
methylation in THC-induced and naïve BM MDSCs. A) DNA methylation near the TSS
of Arg1 in THC-induced and resident BM MDSCs. B) DNA methylation near the TSS of
Stat3 in THC-induced and resident BM MDSCs. Methylation specific (Msp) PCR
products were ran on agarose gel (2%) and densitometry assessed using ImageJ. A)
Methylation index for Arg1, NOS2, and STAT3 in THC-induced and resident BM
MDSCs (fully methylated mouse DNA was used as a control). Data from replicate
experiments (mean±S.E.M) * p < 0.05, ** p < 0.01, *** p < 0.005, **** p< 0.0001
Student's T-Test.
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Figure 2.6: S100A8 protein impacts both MDSC induction and activation.
Conditioned medium (CM) was obtained from THC-induced MDSCs cultured for 5
hours in the presence of PMA and calcium ionophore, and then assessed for suppressive
capabilities. A) Ability of CM to enhance MDSCs or CM as indicated. Thymidine
incorporation was used to detect T cell proliferation and percent suppression when
compared to controls was plotted. B-D) Effect of anti-S100A8 Abs on THC-induced
MDSCs in the peritoneal cavity. Antibody (8H150) against S100A8 was administered 1
hour after THC treatment, and assessed for MDSC accumulation. Data indicate absolute
cell counts of B) Gr1+CD11b+, C) granulocytic MDSCs (Ly6G+LyC+CD11b+), D)
monocytic MDSCs (Ly6G-Ly6C+CD11b+) cells in the peritoneal cavity. E) Effect of
addition of recombinant S100A8 protein (mS100A8) on ability of MDSCs to suppress T
cell proliferation. T cell proliferation was studied by activation using ConA as described
above. The cultures received conditioned medium or mS100A8 as indicated.
Representative data from replicate experiments (mean±S.E.M) * p < 0.05, ** p < 0.01,
*** p < 0.005, **** p< 0.0001 Student’s T-Test or ANOVA/Tukey.
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Figure 2.7: Proposed working model for the mechanism of MDSC induction and
activation by THC
THC treatment causes hypomethylation of genes associated with MDSC function, such as
STAT3, allowing for reduced gene silencing. Additionally, THC treatment increases the
STAT3 activating cytokines IL-6 and IL-10. Phosphorylated STAT3 is then able to bind
the promoter region of S100A8 and Arg1 increasing the suppressive capability of the
THC-induce MDSCs.
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Supplemental Figure 2.1: Arginase1 expression specific to peripheral MDSCs in
THC treated mice.
Western blot with beta actin used for normalization. MDSC-associated protein A)
Arginase1 in MDSCs derived from naïve resident BM and spleen (n=5) and THC treated
mouse peritoneal exudate, BM, and spleen (n=5)
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CHAPTER III: Δ9-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response
via cannabinoid receptor 1 mediated induction of MDSCs.
3.1 INTRODUCTION
Host versus graft disease (HvGD), perhaps better known as transplant rejection, is
primarily a T cell driven process involving recognition of alloantigens that leads to
rejection of allograft cells or tissue. Through the use of immunosuppressive drugs, the
success rate of allogeneic transplants has steadily increased over the years. However, the
chronic use of these drugs often results in major complications in the graft recipient. The
four major categories of immunosuppressive drugs used today include corticosteroids,
calcineurin inhibitors, anti-proliferatives, and mammalian target of rapamycin (mTOR)
inhibitors. These anti-rejection treatments focus largely on halting the alloreactive T cell
activation or proliferation in the host. By causing global inhibition of T cells, the host’s
innate immune system becomes severely impaired (61); (62); (63); (64); (65). For
instance, cyclosporine, a calcineurin inhibitor, can cause immunotoxicity through the
destruction of liver tissue (61); (66). Additionally, anti-proliferatives, such as
mycophenolate (MMF) and mTOR inhibitors, cause leukopenia and can delay
functionality of the graft (62); (63).
Furthermore, use of any severe immune suppressive drug is associated with
increased risk of infection, bacterial or viral, and cancer. Specifically, treatment of
allograft rejection, with current drug options, can result in lymphomas as well as
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accelerated hepatitis infections (67); (68). Such severe drug related issues has
necessitated the continued search for an HvGD treatment which has a better cost to
benefit ratio.
Δ9-Tetrahydrocannabinol (THC) is one of many cannabinoids derived from the Cannabis
sativa plant, which was first described in a 1964 paper by Gaoni and Mechoulam (149);.
THC is a known ligand for cannabinoid receptors 1 and 2 (CB1 and CB2) which were
discovered in the 1990’s (4, 150). CB1 and CB2 are G-protein coupled receptors which
have been shown to be expressed both in the central nervous system (CNS) and the
periphery, including the immune system (3); (12); (13); (14). Upon activation, CB1 and
CB2 receptors are known to modulate adenylate cyclase, both calcium and potassium
channels, reduce T cell proliferation, and have been associated with regulation of the
cytokines leading to a shift from a pro-inflammatory Th1 to an anti-inflammatory Th2
response (151); (152); (153); (154). The anti-inflammatory properties of THC have been
very well characterized by our laboratory and others (77); (155); (156). Recently, we
made an exciting observation that administration of THC results in massive induction of
myeloid derived suppressor cells (MDSCs) (86). MDSCs are innate regulatory cells
which are known to reduce T cell driven inflammatory responses in cancer models (57).
In mice, MDSCs are positive for the cell surface markers CD11b and Gr1 (57). The
heterogeneous population of progenitor and immature cells, which make up MDSCs,
reduce inflammation by producing arginase-1 (Arg-1) and/or iNOS (58).
Currently THC, under the brand name Marinol, has been approved for medicinal
use. Marinol has been used to alleviate pain and nausea associated with cancer
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treatments, stimulate appetite in those with wasting diseases such as HIV/AIDS, and for
spasticity in multiple sclerosis patients (157). Furthermore, our lab recently found that
THC treatment significantly reduces symptomology associated with graft versus host
disease (GvHD), where the immune cells from the allograft attack recipient tissue, in a
cannabinoid receptor dependent manor (78). Based on such studies, we hypothesized that
cannabinoids may have the potential to be used in transplantation (158). To the best of
our knowledge, THC has not been directly tested against allograft rejection in vivo. Due
to the fact that immune cells express cannabinoid receptors and produce
endocannabinoids, studies focused on addressing the role of cannabinoid receptor-ligand
system may offer novel insights into their mechanism of action in enhancing the survival
of an allograft.
In the current study, we found that THC treatment reduces inflammation
associated with HvGD and causes significant increase in the survival of allogeneic skin
allograft. These effects of THC were primarily mediated by its ability to induce
immunosuppressive MDSCs. The current study suggests a role for the cannabinoid
system in the regulation of transplantation immunity and treatment.
3.2 MATERIALS AND METHODS
MiceFemale C57BL/6 (H-2b wild-type, BL6) mice, aged 6-8 weeks and at an average weight
of 20 g, were obtained from the National Cancer Institute (Frederick, MD) and used as
recipients. Female C3H/HeJ (H-2k, C3H) mice, from The Jackson Laboratory, were used
as donors. CB1 KO (-/-) mice (H-2b C57BL/6 background) were a gift from Dr. James
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Pickel, National Institute of Mental Health Transgenic Core Facility. CB2 KO (-/-) mice
(H-2b C57BL/6 background) were obtained from The Jackson Laboratory. The CB1 and
CB2 KO mice were used at 6 weeks of age and averaged 20 g. B6D2F1/J (F1 H-2d/b)
mice aged at least 8 weeks with an average weight of 20 g, obtained from The Jackson
Laboratory, were also used as recipient mice. All mice were housed in pathogen-free
conditions and allowed ad libitum access to filtered water and Teklad rodent diet 8604
(normal chow) at the AAALAC-accredited Animal Research Facility located at the
University of South Carolina School of Medicine. All experiments were conducted under
an approved Institutional Animal Care and Use Committee animal protocol.
Treatment with THC and Induction of Acute HvGDTHC (procured from NIDA-NIH) dissolved in ethanol was diluted in 1xPBS to a
concentration of 20 mg/kg. THC or vehicle (ethanol diluted in 1xPBS) was administered
intraperitoneally (i.p.) at a volume of 0.1mL/mouse, 2 hours prior to allogeneic cell
injection.

To induce HvGD we used a modified localized HvGD model developed by

Shevach et al. (159), which has also been used in other studies (160); (161); (162).
Briefly, acute HvGD was induced by injecting 2.2x107 C3H spleen cells subcutaneously
(SubQ). These cells were split with half injected into the right and left hind flanks, of
BL6 recipient mice. The inguinal draining lymph nodes (IngLN) were harvested daily
for 5 days to study the localized HvGD, following MLR kinetics (163). THC treatment
was continued daily until the termination of the study (day 5). Similarly, cannabinoid
receptor antagonist SR141716 (5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N(piperidin-1-yl)-1H-pyrazole-3-carboxamide; CB1 antagonist), SR144528 (N-[(1S)-endo1,3,3-trimethylbicyclo [2.2.1]heptan2-yl]-5-(4-chloro-3-methylphenyl)-1-[(442

methylphenyl)methyl]-1H-pyrazole-3-carboxamide; CB2 antagonist), and AM-630 (6Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone;
CB2 antagonist) were dissolved in dimethyl sulfoxide (DMSO) containing 20 µL
Tween-80 (Sigma-Aldrich) and then diluted in 1xPBS to a concentration of 20 mg/kg,
cannabinoid receptor antagonist vehicle consisted of DMSO with 20 µL Tween-80
diluted in 1xPBS. Receptor antagonists were administered via i.p. injection at a volume
of 0.1 mL/mouse 1 hour prior to each THC treatment. Vehicle control groups received
ethanol (EtOH) or DMSO diluted in 1xPBS to a similar concentration as treatment
groups.
Monoclonal Antibodies, Reagents, and Flow CytometerAntibodies used for flow cytometric analysis (BioLegend) included: Fc block (93), FITC
conjugated anti-H-2b (KH95), PE conjugated anti-H-2k (15-5-5), Alexa Fluor 488
conjugated anti-CD3e (145-2C11), PE/Cy7 conjugated anti-CD4 (GK1.5), PE conjugated
anti-CD8a (53-6.7), PE/Cy7 conjugated anti-CD25 (PC61), PE/Cy5 conjugated antiCD28 (37.51), PE/Cy5 conjugated anti-CD44 (IM7), PE conjugated anti-CD69 (H1.2F3),
PE conjugated anti-Gr1 (RB6-8C5), and FITC conjugated anti-CD11b (M1/70). HvGD
IngLN and peritoneal exudates were assessed by flow cytometric analysis. Briefly,
IngLN cells (106 cells in 25 µL) from BL6 recipient mice were incubated with Fc
receptor antibodies (5-10 minutes) and incubated with conjugated antibodies (20-30
minutes at 4°C). After incubation with conjugated antibodies cells were washed twice
with 1xPBS/2% fetal bovine serum buffer. The stained cells were then assessed by flow
cytometer (FC500; Beckman Coulter) and the resulting data analyzed by Cytomics CXP
software (Beckman Coulter). All flow cytometer plots were gated on live cells only.
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Two-color flow cytometric analysis was performed for assessing persistence of donor H2k cells in the recipient IngLN, spleen, and peritoneal exudates. Three-color flow
cytometric analysis was used to profile the IngLN response to disease and treatment.
Two-color flow cytometric analysis was used to look for myeloid derived suppressor cell
(MDSC) populations in the peritoneal exudate.
Cytokine and Chemokine AnalysisELISA MAX sandwich enzyme-linked immunosorbent assay (ELISA) kits (BioLegend)
were used to assess the level of IFN-γ, TNF-α, MCP-1, IL-2, and IL-6 cytokines.
Sandwich ELISA kit for G-CSF (Abcam) was also used. Cells from the inguinal lymph
nodes (IngLN, 5x106 cells/mL) from HvGD mice were cultured in 0.2 mL aliquots in 96well round bottom tissue culture plates for 16-20 hours. To assess MCP-1 and G-CSF
levels in the peritoneal exudate, a 1 mL of 1xPBS lavage was collected as described
previously (164). Cytokine production was quantified from cell supernatants (stored at 20°C). Absorbance was measured at 450 nm using a Victor2 1420 Multilable counter
(Wallac).
Thymidine Analysis of Ex Vivo Proliferation due to Allograft RestimulationLymph node cells from HvGD BL6 mice collected 10 days after treatment with THC
injection, were cultured in triplicate (0.2 mL/well in a round bottom 96 well plate) with
mitomycin C-inactivated C3H spleen cells, for 4 days. Sixteen hours before collection
and analysis [3H] thymidine (2 µCi/well) was added to the cell cultures. The
radioactivity was measured using a liquid scintillation counter (MicroBeta Trilux).
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MDSC IsolationSixteen hours after THC injection, mice were euthanized and the peritoneal exudate
collected (86). Briefly, the peritoneal cavity was washed 3x with ice cold 1xPBS (5 mL
per wash) for 5 minutes with agitation to recover cells. The cells were resuspended in 1
mL then treated with Fc block for 10 minutes and labeled with PE-conjugated anti-Gr1.
The +EasySep positive PE selection kit procedure was followed to isolate Gr1 positive
cells, as described previously (105). After isolation cells were labeled with FITC
conjugated anti-CD11b and assessed for purity using flow cytometeric analysis.
MDSC Depletion AssayMDSCs were depleted by the i.p. injection of Ly-6G/Ly-6C purified antibody (RB68C5), as described (165). Depletion antibody was given three hours after every other
THC treatment in doses of 0.1 and 0.05 mg/mouse. Control mice received isotype
matched control Abs. Mice were euthanized at the end of the 5 day model as outlined
previously. Peritoneal exudates were assessed for the presence of MDSCs and H-2k cells
and IngLN were assessed for cellularity and T cell activation.
MDSC Adoptive TransferIsolated THC induced MDSCs (5x106), greater than 95% pure as described earlier (56),
were transferred into BL6 HvGD mice via an i.p. injection 30 minutes after subcutaneous
injection of graft cells. Mice were euthanized 18 or 90 hours after graft injection.
Peritoneal exudates were assessed for the presence of MDSCs and MDSC chemokines,
MCP-1 and G-CSF, and IngLNs were assessed for cellularity and T cell populations.
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Dual Skin Allograft TransplantWe performed dual skin grafts on each recipient mouse; one allograft (right graft bed)
and one autograft (left graft bed). First, graft skin was obtained from the tail of a C3H
donor mouse and transferred into the recipient mice, either BL6 or F1. Secondly, tail
skin grafts from autologous donor mice were transplanted on to the recipient mice, either
BL6 donor to BL6 recipient or F1 donor to F1 recipient. Recipient mice were treated with
THC, or vehicle, 2 hours prior to the skin graft procedure. Mice were kept in protective
casts for 9 days following the graft procedure (166). Grafts were assessed for rejection
starting on day 9 after graft placement. Treatment of either THC or vehicle was given
i.p. every other day for 14 days, and after this point, all treatments were stopped. For
assessment of CB1 receptor involvement, the pharmacological antagonist SR141716A
was given (20 mg/kg) i.p one hour prior to each THC treatment. Mice were scored as +/+
accepted graft, +/- partially rejected graft (less than 50% scabbed over or less than a
halving in graft size), or -/- fully rejected graft. For depicting graft survival +/+ and +/skin grafts were considered viable and -/- skin grafts were nonviable.
Statistical AnalysisHvGD experiments (n≥4 mice per treatment group) were repeated 2 or more times to
ensure repeatability. Skin graft experiments were run in triplicate (n>7 mice was used for
statistical analysis). Data are shown as mean ± S.E.M. Student’s t Test was used to
compare data between two groups. One-way ANOVA with Tukey post-hoc test was used
to compare three or more groups. Log-rank (Mantel-Cox) test was used to determine
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significance of survival curves. Experimental groups were compared to vehicle, p < 0.05
was considered significant.
3.3 RESULTS
THC treatment reduces lymphocyte proliferation in inguinal lymph nodes.
To determine if THC could have a therapeutic role in allograft rejection, we
modified a mouse model of acute HvGD; with a strong and rapid host immune response
to the graft (159). As such, the recipient mice (BL6 haplotype H-2b) were given a bolus
(2.2x107 cells) of graft (C3H haplotype H-2k) splenocytes subcutaneously two hours after
THC (20 mg/kg body weight) or vehicle treatment (ethanol diluted in 1xPBS). Treatment
was administered i.p. daily (Fig. 3.1A). Mice were assessed for symptomology of HvGD
4 days after graft injection, with T cell proliferation and Th1 associated cytokine
secretion being used as markers of disease induction. The draining lymph nodes
(inguinal, IngLN) were collected and assessed for T cell proliferation. The data showed
that total cellularity in the IngLN in HvGD mice was significantly decreased with THC
treatment from the greater than fivefold increase observed in vehicle treated HvGD mice
(Fig. 3.1B). Flow cytometric analysis revealed that T cell subset (CD3+CD4+ and
CD3+CD8+) proportions, were increased in vehicle treated HvGD mice compared to
naive mice (Fig. 3.1 C&D). However, HvGD mice given THC treatment showed a
significant reduction in both T cell populations bringing these T cell numbers back to
naïve levels (Fig. 3.1 C&D).
THC treatment suppresses secretion of pro-inflammatory cytokines.
Previously our lab group has shown that THC treatment can reduce cytokines and
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chemokines associated with inflammatory disease models (76, 84). As HvGD is known
to be accompanied by increases in Th1 associated cytokines, the impact of THC
treatment on the pro-inflammatory environment in the IngLN of HvGD mice was
assessed. Cytokines well known for their involvement in transplant rejection include
IFN-γ and IL-2, which are typically expressed at high levels early after receipt of the
graft, TNF-α, which increases as HvGD progresses, and IL-6, which plays a role in graft
tolerance by skewing the Th1/Th2 balance (59). To this end, the IngLN from THC or
vehicle treated (ethanol diluted in 1xPBS) HvGD mice were collected, 4 days after the
injection of graft cells, and cultured for 24 hours to assess spontaneous cytokine secretion
in the draining lymph node microenvironment . IL-2, a cytokine known to increase T cell
proliferation and IFN-γ, which is associated with cytotoxic T lymphocyte (CTL) killing,
were elevated in vehicle treated mice with HvGD but reduced by nearly 50% upon THC
treatment (Fig. 3.1E left). Additionally, TNF- and IL-6 (Fig. 1E) were over-expressed
in vehicle treated HvGD mice; however, a significant reduction was seen in THC treated
mice. To ensure that THC treatment was in fact targeting the HvGD T cell response
rather than ablating naïve T cell function, mice were treated with THC alone, as a control.
Cell counts in the IngLN (Fig. 3.1B), absolute numbers of CD3+CD4+ and CD3+CD8+
cells in the IngLN (Fig. 3.1 C&D), as well as cytokines (Fig. 3.1E) in mice treated with
THC alone were not changed significantly when compared to naïve mice. Thus, in
subsequent experiments, we primarily compared HvGD+Veh versus HvGD+THC
groups.
Inguinal lymph node activation is decreased by THC administration.
One hallmark of HvGD is that a second transplant with the same haplotype
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disparity will be rejected by the host more rapidly than the initial graft. To determine if
THC could favorably impact this outcome of allograft rejection, HvGD mouse IngLN
were restimulated ex vivo. HvGD mice treated with either vehicle (ethanol diluted in
1xPBS) or THC were rested for 10 days, from the time of the last treatment injection, and
then restimulated with C3H splenocytes. Proliferation due to restimulation was assessed
using [3H] thymidine incorporation. Mice given vehicle treatment showed significantly
increased rates of proliferation compared to THC treated mice (Fig. 3.2A). Having found
that ex vivo restimulation was decreased in THC treated HvGD mice, we next looked at
the number of FasL expressing cells in the IngLN. We found that significantly fewer
cells expressed FasL (Fig 3.2B upper) and that the number of active T cells expressing
the Fas receptor (Fas) was also significantly reduced (Fig. 3.2B lower) in THC treated
HvGD mice. Additionally, T cell activation markers were analyzed to ascertain how
THC affects proliferation rates after treatment. To this end, IngLN were collected 4 days
after graft cell injection from both vehicle and THC treated mice, and evaluated for cells
positively expressing activation markers. Expression of CD25, which is found on
memory T cells and is part of the IL-2 receptor, CD28, a necessary co-stimulatory
molecule that interacts with CD80/86 on APCs, and CD69, an early activation marker,
were assessed in HvGD IngLN by flow cytometry. HvGD mice treated with THC had
significantly fewer CD25+, CD28+, and CD69+ cells in the IngLN than did the vehicle
treated mice (Fig. 3.2C).
THC decreases the inflammatory response allowing for H-2k graft cell persistence.
In HvGD, the final step in graft rejection is apoptosis of the graft cells caused by
CTLs and natural killer (NK) cells (167). Since THC treatment caused a reduction in the
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number and proportion of CD3+CD8+ cells and FasL expression, H-2k positive cells
were evaluated to determine if treatment extended the life of the graft cells. The draining
IngLN, spleen, and peritoneal cavity were selected as possible sites of graft cell
persistence. While no cells positive for H-2k were found in vehicle treated (ethanol
diluted in 1xPBS) HvGD mice (Fig. 3.2D) allograft cells were detected in the peritoneal
cavity of THC treated HvGD mice (Fig. 3.2D). The H-2k+ cells were measurable in the
peritoneal cavity as early as 16 hours after injection of the graft (Fig. 3.2D). To analyze
whether daily THC treatments are sufficiently immunosuppressive to allow for continued
persistence of the graft cells, the peritoneal exudate was monitored at 24 hour intervals.
Interestingly, H-2k+ cells persisted for the entire 90 hour duration of THC treatment (Fig.
3.2E).
THC treatment induces suppressive MDSCs in HvGD mice.
Our laboratory has shown that high levels of Gr1+CD11b+ MDSCs are induced
by a single injection of THC i.p. into mice and that such cells are highly
immunosuppressive (86). To test if THC injection in the current HvGD model also
triggers Gr1+CD11b+ MDSCs, we harvested the cells from the peritoneal cavity, 18
hours after graft injection, and stained them for Gr1+CD11b+ expression. While
HvGD+Veh (ethanol diluted in 1xPBS) treated mice showed less than 3% MDSCs,
equivalent to an absolute count around 0.04x106 cells and similar to naïve mice,
HvGD+THC treated mice showed marked increase in Gr1+CD11b+ MDSC, the
proportion of which increased to 75%, or 3.2x106 cells, at 18 hours and dropped to 46%,
or 2.4x106 cells, at 90 hours (Fig. 3.3A ). As many immature myeloid cells express the
cell surface markers Gr1 and CD11b we looked at the T cell suppressive property of
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these double-positive cells to ensure that they were indeed MDSCs (97); (98). Next, the
Gr1+CD11b+ MDSCs from the peritoneum of THC treated HvGD mice, isolated at 18
hours, were purified (greater than 95% purity Gr1+CD11b+ cells) using positive
selection based on expression of Gr1, as described earlier (56). Isolated MDSCs were cocultured, at various concentrations, in a mixed leukocyte reaction (MLR) with BL6
IngLN as responders and C3H spleen cells treated with mitomycin C, as stimulators (1:8
ratio). Proliferation of the BL6 IngLN cells was measured using thymidine
incorporation. Gr1+CD11b+ MDSCs (from here on denoted as MDSCs) significantly
reduced T cell proliferation in a dose-dependent manner (Fig. 3.3B).
Due to the fact that MDSC induction has been associated with inflammatory
disease, we next set out to show that THC treatment, and not the disease model, was
driving MDSC recruitment (168); (169); (170). Previous studies from our lab
demonstrated that cannabinoid receptor ligand treatment increases the level of MCP-1
(CCL2), which has also been associated with an increase in MDSCs at the tumor site
(75); (171). Additionally, we looked at G-CSF which in our lab has previously been
shown to be elevated in THC-mediated MDSC induction (86). To this end, the
peritoneum exudate was collected, with a single lavage of 1 mL 1xPBS, and assessed for
cytokine and chemokine levels. We found MCP-1 and G-CSF were elevated only in
THC treated HvGD mice (Fig. 3.3 C&D respectively).
THC induced MDSCs play an integral role in in the amelioration of HvGD.
To determine the importance of MDSCs in reducing overall HvGD
symptomology, we used the anti-Ly-6G/Ly-6C purified antibody (RB6-8C5) to deplete
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Gr1+ MDSCs. The depletion antibody was given 3 hours after every other THC
treatment in decreasing doses of 0.1 and 0.05 mg/mouse. The IngLN cellularity for
CD3+CD4+ (Fig. 4A) and CD3+CD8+ (Fig. 3.4B) T cells was significantly increased in
HvGD mice, which was decreased following treatment with THC and control Ab.
Interestingly, HvGD+THC mice that received anti-Ly-6G/Ly-6C Ab showed reversal of
THC effect resulting in increased numbers of T cells (Fig. 3.4 A& B). Additionally, the
impact of MDSC depletion on T cell activation markers including CD25, CD28, and
CD44 was assessed. Upon treatment with anti-Ly-6G/Ly-6C Ab, we saw a significant
increase in cells positive for the CD25, CD28, and CD44 activation markers (Fig. 3.4C).
To ensure that RB6-8C5 depleted the MDSCs, Gr1+CD11b+ cells in the peritoneal cavity
were analyzed. RB6-8C5 caused a stark decrease in MDSC proportion in THC treated
HvGD mice from 67% to about 11% (Fig. 3.4D). Finally, RB6-8C5 administration along
with THC treatment resulted in a significant decrease in the number of H-2k+ cells in the
RB6-8C5 group consistent with a decrease in allograft persistence (Fig. 3.4E).
Because MDSC depletion decreased the efficacy of THC treatment in HvGD
mice, we tested if adoptive transfer of THC-induced MDSCs into allograft recipient mice
would suppress HvGD. MDSCs were isolated from THC treated mice 18 hours after
treatment as outlined previously. Isolated THC-induced MDSCs (5x106), at greater than
95% purity, were then transferred into BL6 HvGD mice via an i.p. injection 30 minutes
after subcutaneous injection of graft cells. Adoptively transferred mice were assessed for
IngLN cellularity and T cell populations four days after the injection of graft cells. We
noted that transfer of MDSCs suppressed the HvGD as indicated by the total number of
cells (Fig 3.5A) as well as CD3+CD4+ and CD3+CD8+ T cell subsets (Fig 3.5B),
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although to a lesser extent than THC. Additionally, we looked at the peritoneal exudate
for MDSC persistence as well as MDSC homing cytokine levels (18 hours after graft cell
injection). When the peritoneal exudate was enumerated for Gr1+CD11b+ cells in
MDSC transferred HvGD mice, we found that there were significantly reduced numbers
of MDSCs in the peritoneal cavity compared to the THC treated group (Fig. 3.5C). In
corroboration with reduced overall cellularity within the peritoneum, the proportion of
persisting H-2k+ cells was reduced by 50% in MDSC treated compared to THC treated
HvGD mice (data not shown). In addition, MCP-1 and G-CSF were undetectable in mice
adoptively transferred with MDSCs when compared to those exposed to THC which
showed very high levels (Fig 3.5 D&E). These data showed that adoptively transferred
MDSC may be less effective because they may not be able to survive or home.
THC-mediated reduction of HvGD occurs in a CB1 dependent manner.
Immune cells express both CB1 and CB2 receptors, as such specific antagonists
were used in vivo to ascertain whether THC was working preferentially through
activation of CB1, CB2, or both receptors (13); (78); (28); (75). BL6 mice were treated
with CB1 or CB2 receptor antagonist (SR141716 or SR144528 respectively at 20 mg/kg
i.p.) one hour prior to each THC treatment. As seen earlier, HvGD+THC mice showed
decreased absolute cellularity of the IngLN when compared to HvGD+Veh (DMSO+20
µL Tween-80 diluted in 1xPBS) mice. Interestingly, HvGD+THC+CB1 antagonist
treated mice but not HvGD+THC+CB2 antagonist treated mice showed a reversal in
IngLN cellularity when compared to HvGD+THC mice, thereby suggesting that THC
was acting through CB1 but not CB2 receptors (Fig. 3.6A). To further corroborate that
the CB2 receptor was not involved, we used another CB2 receptor antagonist (AM630)
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(14), and found that this antagonist was also not able to reverse the effect of THC on
HvGD (Fig. 3.6B). As confirmation that THC was working through the CB1 receptor,
CB1 KO mice were incorporated into the HvGD model as recipients. Thus, we induced
HvGD in BL6 wild-type and CB1 receptor KO mice and treated them with THC. The
data indicated that THC treatment did not reduce IngLN cellularity in HvGD mice with a
nonfunctional CB1 receptor compared to THC treated wild-type HvGD mice (Fig. 3.6C).
Next, we studied MDSC induction in wild-type, CB1 KO, or CB2 KO allograft recipient
mice and found that the proportion of MDSCs in the peritoneal exudate was 84%, in wild
type BL6 mice, while CB1 KO mice had 25%, and CB2 KO mice had 63% (Fig. 3.6D).
Looking not only at MDSC proportion but also absolute cell counts we also noted a
significant reduction from CB1 but not CB2 KO mice, 8.6x106 and 17.1x106 cells
respectively, when compared to wild-type mice which averaged 16.2x106 peritoneal
exudate MDSCs (Fig. 3.6E).
THC significantly extends life of allogenic skin grafts.
While all of the data shown above indicated that THC can suppress HvGD, we
next tested directly whether THC treatment could reduce rejection of complete haplotype
mismatched skin allografts. To this end, tail skin from donor C3H mice, kept in place on
the recipient mouse using a compression cast in lieu of sutures, acted as a complete
mismatch allograft (166). The cast was removed after nine days. Allograft rejection was
assessed daily starting on day 9 after transplant, 1 hour after cast removal. Mice were
treated with either THC or vehicle (ethanol diluted in 1xPBS) every other day for 14 days
via i.p injection as described earlier. The data showed that the skin allograft survival
curve for THC treated BL6 recipient mice, mean survival >12 days, was significantly
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extended compared to vehicle-treated mice, mean survival <10 days (Fig. 3.7A).
Axillary and brachial LNs, from the skin transplant mice, were restimulated with
mitomycin C treated C3H splenocytes, ex vivo, and proliferation analyzed using
thymidine incorporation. THC treated skin graft recipient mice showed significantly less
proliferation than did vehicle treated graft mice (Fig. 3.7B). In order to show that the
protective effects of THC on the skin allograft were not specific towards one MHC
haplotype, we moved our dual graft model into B6D2F1/J mice which have a different
haplotype disparity H-2d/b than BL6 mice when compared to the H-2k allograft. We again
found that THC treatment was able to significantly extend the skin allograft survival
curve, mean survival =12 days, compared to vehicle treatment, mean survival <10 days
(Fig. 3.7C). Furthermore, having shown that CB1 receptor function was integral in
reducing the inflammatory response to allograft cells we used the antagonist
(SR141716A) along with THC treatment in the BL6 skin graft model. A significant
reduction in the life of the skin graft was observed upon pharmacologically blocking the
CB1 receptor, mean survival <11 days, compared to THC treatment without CB1
receptor antagonist, mean survival =14 days (Fig. 3.7D).
3.4 DISCUSSION
While the immunosuppressive properties of THC have been well elucidated,
whether THC can be used to prevent allograft rejection has not been previously studied
(172). Recently, we suggested that activation of cannabinoid receptors may provide a
novel approach to prevent transplant rejection (158). THC has been found to affect
nearly every aspect of cellular immunity including T cells, natural killer cells,
macrophages, neutrophils, mast cells, and B-cells (as reviewed throughout the years
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(155); (173); (174); (175); (77); (3, 155). It has also been established that THC can impact
the biasing of T cell differentiation from Th1 to Th2 (154); (176); (177); (88)). Moreover,
THC can also induce immunosuppressive cells such as MDSCs and Tregs (86); (88);
(78)). Thus, it is worth investigating if THC can suppress allograft rejection.
In the current study, we found that THC-induced MDSCs may play a critical role
in suppressing allograft rejection. This was evident from experiments using the antibody,
RB6-8C5, which depleted the MDSC in vivo and caused a reversal of the ability of THC
to ameliorate HvGD. THC-induced MDSCs suppressed the T cell proliferation against
the allogeneic cells in vitro. Furthermore, adoptive transfer of THC-induced MDSCs into
HvGD mice caused significant suppression of HvGD response. Together, these data
provided strong support to the fact that THC may suppress allograft rejection through
induction of MDSCs. Our laboratory has shown previously that THC treatment triggers
rapid and massive induction of MDSCs in naïve mice after a single dose (86). While
MDSCs were first associated with cancer as part of the tumor microenvironment which
decreased T cell based anti-tumor immunity and increased tumor progression, recent
studies have indicated that MDSCs may also be induced at sites of inflammation (57,
178); (179). The suppressive functionality of MDSCs is most commonly attributed to the
release of Arg-1 or iNOS (58). THC-induced MDSCs have been shown to be suppressive
to T cell proliferation in response to both polyclonal and antigen-specific stimuli (86).
The importance of MDSCs in creating tolerance in grafts was shown recently through the
adoptive transfer of LPS-induced MDSCs i.v. (60). The transfer of MDSCs delayed the
rejection of minor antigen disparity, HY, skin grafts (60). MDSCs were also present in
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tolerated grafts including MHC-mismatched kidney transplants in rats (98). Additionally,
the suppressive function of MDSCs was deemed vital, as MDSCs unable to produce Arg1 via IL-13 treatment were less effective, in ameliorating GvHD in lethally irradiated
BALB/c mice (180). However, adoptive transfer of MDSCs was not sufficient to cause
graft persistence in fully mismatched antigen disparity (60). In the current study, we
found that the adoptive transfer of THC-induced MDSCs, suppressed the immune
response in the LN of mice with HvGD and reduced the total numbers of cells, including
CD3+CD4+ T cells and CD3+CD8+ T cells, although this was not as effective as
administration of THC alone. These data suggested that MDSCs, at least in part, play a
role in THC-mediated suppression of allogeneic response in the recipient. THC may be
more effective in vivo because immunosuppression can be induced through additional
mechanisms such as induction of Tregs, switch from Th1 to Th2 , apoptosis in activated
T cells , and suppression of cytokines (88); (78); (154); (176); (80); (181); (84).
Alternatively, treatment with MDSCs may not be as effective because the cells may not
be able to maintain an immature, and therefore suppressive, phenotype after adoptive
transfer or may not migrate to the grafted site to mediate suppression unlike those
MDSCs directly induced by THC. We concluded this was due to lack of MDSC homing
cytokines, such as MCP-1 and G-CSF, which are necessary for MDSC migration and
retention of suppressive capabilities (182). The findings of De Wilde et al., which show
that MDSCs are directly involved in tolerance lend credence to our findings that THC, a
known MDSC inducer, reduces HvGD symptomology, attenuating acute transplant
rejection (60).
In the current study, we noted that THC-mediated effect on allograft response was
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regulated through CB1 rather than CB2 receptors. Recently, a study looking at Mixed
Lymphocyte Reaction (MLR) in vitro found that the CB2 receptor was necessary for
THC induced T cell suppression (183). The findings of Robinson et al showed a CB2
dependent decrease in IL-2 production however the role of MDSCs was not assessed in
the study (183). We found that THC was able to significantly reduce the in vivo
proinflammatory response, including T cell activation and proliferation, to allograft in
wildtype BL6 mice with functional CB1 and CB2 receptors. However, when the
functionality of the CB1 receptor was compromised, either by genetic knock out or
pharmacological blockade, THC was less effective in inhibiting the proinflammmatory
response including T cell proliferation. In contrast, a loss of CB2 receptor function had
little to no impact on THC mediated immunosuppression. The observation that CB1
activation was necessary for HvGD amelioration was explained in part when the role of
cannabinoid receptors in MDSC induction was observed. We showed that THC mediated
induction of MDSCs, in this model, was dependent on a functional CB1 receptor.
Additionally, THC-mediated shift in T cell differentiation from Th1 to Th2 has recently
been found to involve both the CB1 and CB2 receptors (154). Newton et al. found that
the shift was due to the CB1-dependent decrease in IL-12Rβ1 binding and a CB2dependent increase in GATA-3 expression (154). Together, CB1 and CB2 activation
creates a simultaneous drop in IFN-γ and rise in IL-4. The role of CB1 in T cell
differentiation brings to light the often overlooked involvement of this receptor with
peripheral immune cells. While CB2 is expressed at higher levels in naïve immune cells,
CB1 expression has been found to be elevated upon activation, specifically in T cells (34,
184). Furthermore, THC treatment of T cell lines, in lieu of activation, resulted in
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elevated CB1 levels (185). Together these findings support our claim that THC is
working in a CB1 receptor dependent manner.
In the current study, we found that THC treatment in HvGD mice led to
significant suppression of proinflammatory cytokines. In particular THC significantly
reduced the secretion of IL-2, IL-6, and IFN-γ which are associated with the loss of graft
function and ultimately lead to allograft destruction. Our lab has reported that THC
treatment in an autoimmune hepatitis model can reduce both TNF-α and IL-6 levels in
serum (76). Furthermore, THC treatment led to reduced IL-2 and IFN-γ secretion in
ConA activated splenic T cells (186). In addition to reducing proinflammatory cytokines,
necessary for T cell proliferation, THC can also reduce the expression of receptors
necessary for T cell activation. We found that THC was able to significantly reduce the
number of cells expressing CD25, CD28, CD69, and CD44 co-stimulatory and activation
markers in HvGD mice. Additionally, THC treatment brought the expression of these T
cell activation receptors to levels not significantly different from naïve mice. It has been
shown that the co-stimulator ICOS, expression and transcription, can be down regulated
via THC treatment of anti-CD3/CD28 stimulated CD4+ splenic T cells (187).
Cannabinoid receptor binding has also been found to inhibit T cell activation through costimulator interference. Focusing on the role of APCs in T cell activation, a recent study
found that heat-stable antigen expression was decreased on macrophages upon THC
treatment resulting in extended T cell unresponsiveness (103). Furthermore, CD28
blockade is known to play a major role in tolerance, though not sufficient to prevent graft
rejection. While there has been no direct evidence which ties THC to the depletion of the
co-stimulatory molecule CD28, it is known that THC treatment inhibits pathways
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associated with CD28 binding (139). CD28 activation is involved in PI3K/AKT and NFκB proliferative pathways. Binding of CD28 to PI3K, PKC-θ, or Grb2 have all been
suggested as NF-κB activation regulating pathways (188). NF-κB activation is important
in graft rejection as recent literature shows that impaired NF-κB activation can be
correlated to skin graft tolerance (189). The fact that PI3K subunit p110δ is upregulated
in transplanted HY-mismatched heart graft tissue suggests that the CD28/PI3K/NF-κB
pathway could be integral in rejection (190). It has been known for some time that THC
treatment inhibits NF-κB DNA binding, and that high levels of IL-10 can suppress PI3K
binding of CD28 (139); (191). The research reported here acts as a bridge to these
concepts. Additionally, reduced CD28 co-stimulation, as well as THC treatment, has
been implicated in the development of anergy in mouse lymphocytes (192); (193). As
such, we suggest that THC treatment; induces an increase in Th2 cytokines which inhibit
CD28 binding thereby reducing NF-κB and allowing for graft tolerance.
Together, the current study shows for the first time that cannabinoid receptorligand system may play a critical role in allograft rejection. THC treatment reduced the T
cell response in the host by dampening the secretion of pro-inflammatory cytokines and
expression of T cell activation markers. Additionally, THC treatment resulted in delayed
graft destruction even in a major histocompatibility complex disparity model of allogenic
skin transplant. Induction of highly immunosuppressive MDSCs following THC
treatment proved to be necessary, at least in part, for THC-mediated attenuation of
allograft rejection. We also noted that this effect of THC was dependent on activation of
CB1 rather than CB2 receptors. The current study sets the stage for additional studies on
the cannabinoid system in regulating transplant rejection involving potential
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manipulation of endocannabinoids, receptors, as well as use of cannabinoid receptor
select agonists that are not psychoactive.
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Figure 3.1: THC treatment ameliorates HvGD.
C57BL/6 (BL6) mice were given THC or vehicle, ethanol diluted in 1xPBS, (n=5 mice
per group) 2 hours prior to graft cells (C3H 2.2x107 subcutaneously) and daily after graft
injection until sacrifice. On day 4 after allograft injection, T cell populations were
assessed by harvesting draining inguinal lymph nodes (IngLN) and then triple-staining
the cells with fluorochrome-labelled antibodies against CD3, CD4, and CD8 antigens.
IngLN cells, collected on day 4 after allograft injection, were also cultured for 24 hours
and supernatants harvested to assay the spontaneously produced Th1 cytokines. (A)
Schematic of procedure and treatment regimen. (B) Absolute cell count in the IngLN.
(C-D) Absolute number of CD3+CD4+ (C) and CD3+CD8+ (D) cells in the IngLN. (E)
Spontaneous secretion of IL-2, IFN-γ, TNF-α, and IL-6. Representative data of 3
experiments shown (mean ± S.E.M). * p < 0.05, ** p < 0.01, *** p < 0.005, **** p<
0.0001 Student’s t test.
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Figure 3.2: THC treatment reduces lymphocyte activation in the recipient mice and
allows for allograft persistence.
IngLNs were harvested from BL6 HvGD mice (n=5 mice per group) 10 days after final
THC treatment, day 14 after allograft injection. Next, IngLNs were harvested and
restimulated in vitro with donor C3H spleen cells (mitomycin C inactivated).
Proliferation of IngLN cells was assessed 4 days after in vitro restimulation using [3H]
thymidine. IngLN activation status was determined 4 days after allograft injection by
individually staining the cells for antibodies against CD25, CD28, and CD69 antigens.
(A) C3H restimulation in vehicle, ethanol diluted in 1xPBS, and THC-treated HvGD mice
(data shown as mean ± S.E.M). (B) T cell activation marker expression, CD25, CD28,
and CD69 on IngLN cells (similar results seen in two replicate experiments). (C) H-2k
cell persistence in recipient mice. (D) H-2k cell persistence in the peritoneal cavity
throughout the five days (similar results seen in replicate experiments). * p < 0.05, ** p
< 0.01, *** p < 0.005, **** p< 0.0001 Student’s t test.

63

Figure 3.3: THC treatment induces immunosuppressive MDSCs.
Cells were isolated from peritoneal exudates (n=5 mice per group) either18 or 90 hours
after graft injection, and stained for Gr-1 and CD11b stained to identify MDSCs, MDSCs
were also isolated using positive selection PE-magnetic beads for Gr1. C3H cells and
MDSCs were mitomycin C inactivated prior to plating with BL6 IngLN cells.
Proliferation of IngLN cells was assessed 4 days after MLR stimulation using thymidine.
(A) Gr1+CD11b+ MDSCs in the peritoneal cavity, at 18 and 90 hours after graft cell
injection, (similar results seen in replicate experiments). (B) MDSC suppression of MLR
against C3H cells (p<0.01, one-way ANOVA and Tukey HSD post-hoc test). (C, D)
Peritoneal exudates were collected 18 hours after graft injecion (1 mL ice cold 1xPBS)
and assessed for MDSC homing cytokines, MCP-1 (CCL2) and G-CSF. Representative
data of replicate experiments shown (mean ± S.E.M). * p < 0.05, ** p < 0.01, *** p <
0.005, **** p< 0.0001 ANOVA/Tukey.
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Figure 3.4: Role of MDSCs in HvGD modulation as determined via MDSC
depletion.
MDSCs were depleted by i.p. injection of Ly-6G/Ly-6C purified Ab (RB6-8C5) or
isotype matched control Ab (n=5 mice per group). Depletion Ab was given three hours
after every other THC treatment in decreasing doses of 0.1 and 0.05 mg/mouse.
Peritoneal exudates were assessed for the presence of MDSCs and donor H-2k cells, and
IngLN were assessed for cellularity and T cell activation, day 4 after graft injection. (A)
Absolute cell count of CD3+CD4+ T cells in IngLN. (B) Absolute cell count of
CD3+CD8+ T cells in IngLN. (C) T cell activation marker expression, CD25, CD28,
and CD44 (right), on IngLN cells. (D) Proportion of MDSCs in the peritoneal cavity.
(E) Allograft cell persistence at the conclusion of the five day experiment.
Representative data of 3 experiments shown (mean ± S.E.M). * p < 0.05, ** p < 0.01,
*** p < 0.005, **** p< 0.0001 Student’s T test or ANOVA/Tukey.
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Figure 3.5: Role of MDSCs in HvGD modulation as determined via adoptive
transfer.
Isolated THC induced MDSCs (5x106), greater than 95% pure, were transferred into BL6
HvGD mice (n=5 per group) via an i.p. injection 30 min after subcutaneous injection of
graft cells. Mice were euthanized at two time points day 4, for IngLN analysis, and 18
hours, for peritoneal lavage analysis, after graft injection. Peritoneal exudates were
assessed for the presence of MDSCs and the MDSC homing chemokines. (A) Cellularity
in the IngLN. (B) T cell populations, CD3+CD4+ (top) and CD3+CD8+ (bottom), in
IngLN. (C) Overall MDSC cellularity of the peritoneal cavity. (D) MCP-1 levels in the
peritoneal exudate. (E) G-CSF levels in the peritoneal exudate. Similar results seen in
replicate experiments (mean ± S.E.M). * p < 0.05, ** p < 0.01, *** p < 0.005, **** p<
0.0001 ANOVA/Tukey.
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Figure 3.6: THC works through the CB1 receptor to ameliorate HvGD.
BL6 mice (n=5 per group) were given either CB1 or CB2 receptor antagonist 1 hour prior
to treatment with THC or vehicle, DMSO+20 µL Tween-80 diluted in 1xPBS. (A)
Absolute cellularity in IngLN, day 4 after graft injection, using CB2 and CB1 receptor
antagonists, SR144528 and SR141716A respectively (data shown as mean ± S.E.M). (B)
Absolute cellularity in IngLNs, day 4 after graft injection, using CB2 receptor antagonist
AM630 (data shown as mean ± S.E.M). (C) Cellularity on IngLn in BL6 and CB1 KO
HvGD mice, day 4 after graft injection. (D) THC induction of peritoneal MDSCs in
BL6, CB1 KO, and CB2 KO HvGD mice, 18 hours after graft injection (mean ± S.E.M).
(E) Absolute cell counts of peritoneal MDSCs in BL6, CB1 KO, and CB2 KO HvGD
mice. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p< 0.0001 Student’s T test or
ANOVA/Tukey.
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Figure 3.7: THC treatment significantly extends survival of allogenic skin grafts.
The dual skin graft method was used to include a technical control (all autograft skin
transplants survived). THC treatment was given every other day for two weeks. (A)
C3H allograft on BL6 recipient mice: survival of allograft in THC and vehicle (ethanol
diluted in 1xPBS)-treated mice (mean ± S.D. n=9 vehicle treated mice and an n=9 THC
treated mice). (B) Skin graft rejection mice from panel A were rested ten days (from the
last treatment) and then the axillary and brachial lymph nodes were restimulated ex vivo
with C3H splenocytes. Thymidine assay was used to determine proliferation. (C) C3H
allograft on B6DF1/J (F1) recipient mice: survival of allograft in THC and vehicletreated mice (mean ± S.D. n=8 vehicle treated mice and an n=9 THC treated mice). (D)
C3H allograft on BL6 recipient mice survival of allograft in THC or SR141716A+THCtreated mice (mean ± S.D. n=6 SR141716A+THC treated mice; and an n=4 THC treated
mice). Log-rank test (survival curves) and ANVOA/Tukey * p < 0.05, ** p < 0.01, *** p
< 0.005, **** p< 0.0001.
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CHAPTER IV: Δ9-Tetrahydrocannabinol attenuates delayed type hypersensitivity via
microRNA regulation of Th1 and Th17 differentiation.
4.1 INTRODUCTION
T helper cell differentiation, has classically, represented distinct T cell lineages
impacted by cytokine milieu, Th1 (IL-12), Th2 (IL-4), Th17 (IL-6 and TGFβ), and T
regulatory cells (Tregs- TGFβ), leading to terminally differentiated T cell subsets (51).
Over the years, it has been shown that interaction between T helper cell subsets, such as
Th1 and Th2, can regulate the differentiation of other T cell lineages (194); (195). While
the Th1, proinflammatory, versus Th2, anti-inflammatory, responses have been clearly
defined (as reviewed though the years (196); (197); (198); (199); (200) the discovery of
additional proinflammatory T helper cell populations, such as Th17, has complicated our
understanding of T cell interactions. Recent evidence has shown that Th1 secreted
cytokines, IFN-γ and IL-2, can inhibit Th17 differentiation and that while IL-17a/f
expression cannot directly inhibit the Th1 responses, elevated levels of TGFβ associated
with active Th17 cells can (201); (202); (203); (204). Further muddling these
proinflammatory cell interactions is the fact that Th17 and Th1 lineages may have some
overlap due to immune cell plasticity and the emergence of proposed Th17/Th1 and
“non-classic” Th1 lymphocytes (205); (206); (207); (208); (209).
Heritable genetic modifications, known as epigenetics, have arisen recently as the
explanation for selective gene expression (35); (36).
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Epigenomics broadly encompasses

DNA methylation, histone acetylation and methylation, as well as microRNA (miRNA or
miR) expression. Evidence now exists which highlights the influence of epigenetic
modifications on immune cell differentiation and activation (38); (210); (211); (212);
(88); (213). miRNA, ~20 nucleotide long strands of RNA, most commonly inhibit gene
expression through the binding of mRNA sequences (40). Each miR can bind numerous
targets and therefore regulate the expression of multiple genes (40). Interestingly,
lineage-defining transcription factors and the downstream targets associated with T
helper cell subsets have become a major focus for epigenetic modification such as
miRNA binding (49); (50).
Inflammation seen in delayed type hypersensitivity (DTH), plays a critical
protective role against intracellular pathogens. However, such inflammation, is often
seen against innocuous non-pathogenic antigens leading to sever damage to the tissue as
seen during contact dermatitis against nickel or poison ivy. Classically, DTH was
considered to be a Th1 driven inflammatory disease; however treatment with anti-IFN-γ
showed that such mice continue to exhibit signs of DTH (69). More recently, the
importance of Th17 cells in DTH disease progression was highlighted in IL-17 knockout
mice which showed significantly reduced ear swelling in an allergenic contact dermatitis
model (52). Thus, depending on the antigen, it is likely that both Th1 and Th17 cells play
an effector cell role.
Immune cells are well established to express cannabinoid receptors, while their
precise role in the regulation of immune response remains unclear. ∆9Tetrahydrocannabinol (THC), one of the most well studied bioactive cannabinoids
derived from the Cannabis sativa plant, has long been shown to reduce T cell driven
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inflammation via; apoptosis, induction of immuneoregulatory cells, regulation of T helper
cell cytokines, and even epigenetic modifications (79); (84); (76); (86); (154); (87); (88);
(38); (214). Majority of THC research, in regards to inflammation and autoimmunity,
has centered on the Th1/Th2 axis. Specifically, we and others, have found that THC
treatment increases anti-inflammatory cytokines, causing a subsequent drop in
proinflammatory cytokines such as IL-12, IFN-γ, and TNF-α, and reduced T cell
activation (154); (186); (79); (84). THC treatment has also been found to induce Tregs
which are known to inhibit both Th1 and Th17 lineage differentiation (76); (88); (215).
Furthermore, THC has been found to significantly reduce cytokines associated with Th17
differentiation such as IL-6 and IL-17a (216). Recently, our lab has found that the ability
of THC to shift the immune response from proinflammatory to anti-inflammatory
involves, in part, miRNA regulation (87); (88).
While cannabinoid receptor agonists can attenuate DTH, the role of THC in regulation of
epigenetic modifications has not been assessed (217); (218); (83). Furthermore, the
ability of THC treatment to inhibit both Th1 and Th17 differentiation within a
hypersensitivity model has not been reported. With this in mind, we set out to determine
if THC treatment could inhibit both Th1 and Th17 T cell lineages, in a methylated BSA
(mBSA) sensitization/rechallenge model of DTH, via miRNA regulation. Our results
suggest that THC can attenuate DTH response to mBSA by inhibiting both Th1 and Th17
cells through reversal of the miRNA alterations brought about during the DTH response.
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4.2 MATERIALS AND METHODS
MiceFemale C57BL/6 (BL6) mice, aged 6-8 weeks and at an average weight of 20 g, were
obtained from Harlan Laboratories. All mice were housed in pathogen-free conditions
and allowed ad libitum access to filtered water and Teklad rodent diet 8604 (normal
chow) at the Animal Research Facility located at the University of South Carolina School
of Medicine. All experiments were conducted under an approved Institutional Animal
Care and Use Committee animal protocol.
Induction of delayed type hypersensitivity (DTH) and THC treatmentDTH was induced in C57BL/6 mice using a sensitization/rechallenge method (83).
Briefly, mice (n=5 per experimental group) were sensitized with a subcutaneous injection
(100 µL/hind flank) of 1.5 mg/mL methylated BSA (mBSA- Sigma Aldrich) emulsified
in complete Freunds adjuvant (CFA- Sigma Aldrich). Six days later, the mice were
rechallenged with a footpad injection (20 µL/footpad) of 10 mg/mL mBSA in 1xPBS.
∆9-Tetrahydrocannabinol (THC- NIDA-NIH) dissolved in ethanol was diluted in 1xPBS
to a concentration of 20 mg/kg. THC or vehicle (ethanol diluted in 1xPBS) was
administered intraperitoneally (i.p.) at a volume of 0.1 mL/mouse into DTH mice daily
starting on Day 3. Percent swelling was measured as [(Thickness(mBSA rechallenged
footpad) - Thickness(1xPBS rechallenged footpad)) / Thickness(1xPBS rechallenged
footpad)] * 100.
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Monoclonal antibodies, reagents, and flow cytometerAntibodies used for flow cytometric analysis (BioLegend) included: Fc block (93), PE
Cy7 conjugated anti-CD3 (145-2C11), PE conjugated anti-CD19 (6D5), FitC conjugated
anti-CD69 (H1.2F3), FitC conjugated anti-IL17a (TC11-18H10.1), and PE conjugated
anti-CD4 (GK1.5). In short, popliteal lymph node cells (PopLN- 106 cells in 25 µL) from
rechallenged BL6 mice were incubated with FC receptor antibodies (5-10 minutes) and
incubated with conjugated antibodies (20-30 minutes at 4°C). After incubation with
conjugated antibodies cells were washed twice with 1xPBS/2% fetal bovine serum buffer.
The stained cells were then assessed by flow cytometer (FC500; Beckman Coulter) and
the resulting data analyzed by Cytomics CXP software (Beckman Coulter). Intracellular
Cytokine Staining Kit (BD biosciences) was used for IL-17a staining per manufacturer’s
specifications. Briefly, cells were first stained for cell surface CD4 receptor and then
fixed/permeablized. Fixed/permeabolized cells were then stained for IL-17a. Three-color
flow cytometric analysis was used to profile the lymphocyte activation. Two-color flow
cytometric analysis was used to look for Th17 cell differentiation.
Thymidine analysis of lymph node proliferationDraining lymph node cells from mBSA sensitized mice (1.5 mg/mL in vivo) were cocultured in triplicate (0.2 mL/well in a round bottom 96 well plate) with mBSA (40
mg/mL) for 48 hours. Sixteen hours before collection and analysis [3H]thymidine (2
µCi/well) was added to the cell cultures. The radioactivity was measured using a liquid
scintillation counter (MicroBeta Trilux).
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Histological assessment of rechallenged footpadFootpads from THC- or vehicle-treated DTH mice were isolated for histological
examination. Rechallenged feet were cut distal to the ankle and decalcified/fixed in CalRite (Fisher scientific). The footpad was then embedded in paraffin and sectioned into
6µm sections and stained for Hematoxylin and Eosin (H&E) for assessment of edema and
immune cell infiltration (83).
Cytokine analysis in cell culture supernatantsELISA MAX sandwich enzyme-linked immunosorbent assay (ELISA) kits (BioLegend)
were used to assess the level of IL-17a/f, IFN-γ, and TNF-α cytokines. Cells were isolated
from spleen and draining lymph nodes of DTH mice, plated at 1x106 cells/well, cultured
overnight (18-20 hours) for spontaneous cytokine secretion in complete RPMI media (1%
v/v penicillin/streptomycin, 1% v/v HEPES buffer, 10% v/v heat inactivated FBS, and
0.0002% v/v 2-mercaptoethanol). Cytokine production was quantified from cell
supernatants (stored at -20°C). Absorbance was measured at 450 nm using a Victor2
1420 Multilable counter (Wallac).
qPCR analysis of gene expressionTotal RNA was isolated and purified using miRNeasy kit (Qiagen), following
manufacturer’s procedure. iScript cDNA synthesis kit (BioRad) was used according to
manufacturer’s specifications to reverse transcribe cDNA. qPCR was performed using
Sso Advanced SYBR Green (BioRad) on a CFX Connect (BioRad). Samples were
assessed for expression of β actin, Tbx21 (Tbet), RORγT, IRF4, Pten, NFκB, IFN-γ, and
SMAD7. Primers, as found on PrimerBank (Harvard Medical School), were synthesized
from IDT DNA technologies with annealing temperatures of 60°C (Table I).
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microRNA (miRNA or miR) array and array analysisAffymetrix miRNA array version 4, which integrates all mature miRNA sequences in
miRBase Release 20 (miRBase v20), was used to profile miR expression in the PopLN
24 hours after mBSA rechallenge in DTH mice. The array identified over 3,000 unique
mouse miRs as identified in miRBase v20 using the FlashTag biotin HSR hybridization
technique, as previously described (87). In brief, log transformation of fluorescent
intensities obtained from the hybridization was used to generate heat maps. Hierarchical
clustering, using Ward’s method, and similarities were measured using half square
Euclidean distance. Fold changes in miR expression were obtained from the raw array
data, and only those miRs with greater than 2.0-fold change were considered for further
analysis. miR predicted targets, alignments, and miR SVR scores were determined using
online databases (TargetScan, microRNA.org, and miRWalk). Determination of miR
interaction and pathway analysis was completed using Ingenuity Pathway Analysis (IPAIngenuity Systems). Venn diagram construction was done using LucidChart Venn
diagram maker (https://www.lucidchart.com/pages/examples/venn_diagram_maker).
miR validation in PopLN cellsmiR levels were validated using miScript II RT kit (Qiagen), following manufacturer’s
specifications for 5x miScript HiSpec Buffer. qPCR was performed using miScript
SYBR Green (Qiagen) on CFX Connect (BioRad). Samples were assessed for
expression of SNORD96A, miR-21a-5p, miR-223-3p, miR-29b-3p, miR-125a-5p, and
miR-142-5p (Qiagen).
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miR transfection of primary cellsTransfection of primary cells was completed using the HiPerFect Transfection kit
(Qiagen) following the manufacturer's protocol. Briefly, DTH draining lymph node cells
were plated (4x105 cells/well) in complete RPMI media. Transfection, 6 hours at 37°C,
with mimic (40 ng/well), inhibitor (100ng/well), and negative mimic (Negative Control
siRNA- 40 ng/well) was done in serum free RPMI media (1% v/v
penicillin/streptomycin, 1% v/v HEPES buffer, and 0.0002% v/v 2-mercaptoethanol)
with 6µL HiPerFect transfection reagent. Transfection complex was added one drop at a
time into cell culture. Transfection mimic, inhibitor, and negative mimic were purchased
from Qiagen. Twenty-four hours from initial incubation cells were collected, total RNA
isolated (miRNeasy kit- Qiagen), and cDNA reverse transcribed (miScript II RT kitQiagen) for miR validation and target gene expression analysis.
Statistical analysisData is shown as mean ± S.E.M. Student’s t-test was used to compare data between two
groups. One-way ANOVA with Tukey post-hoc test was used to compare three or more
groups. Experimental groups were compared to controls, p < 0.05 was considered
significant.
4.3 RESULTS
Hypersensitivity is decreased in THC treated DTH mice
Delayed type hypersensitivity (DTH) is a T cell driven response to antigens,
mediated primarily by Th1 and Th17 cells. In the current study, we used methylated
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BSA (mBSA) as an antigen to induce DTH in the mouse footpads as described previously
(83). Briefly, mice were sensitized by injecting mBSA (1.5mg/mL in CFA) into the
footpads on day 0 followed by rechallenge with mBSA on day 6 (10mg/mL in 1xPBS)
(Fig. 4.1A). These mice received 20 mg/kg THC or vehicle (ethanol diluted in 1xPBS)
on days 4, 5 and 6 after initial sensitization (Fig. 4.1A). We used relative percent
swelling of footpad as the primary indicator of DTH response 24 hours after rechallenge
with mBSA. THC treatment of DTH mice significantly reduced swelling in the hind
footpad compared to vehicle treatment (Fig. 4.1B) as well as draining lymph node
(popliteal lymph node, PopLN) cellularity (Fig. 4.1 C). Additionally, we looked at
lymphocyte proliferation, due to ex vivo rechallenge (40 mg/mL mBSA) of sensitivzed
draining lymph nodes, via [3H]thymidine incorporation. We found that THC treatment
was able to significantly decrease mBSA induced lymphocyte proliferation compared to
vehicle treated DTH mice (Fig. 4.1D). Moreover, histological analysis showed reduced
swelling in THC-treated mice correlated with a significant decrease in lymphocyte
infiltration in the rechallenged footpad (Fig. 4.1 E-H).
THC treatment reduced lymphocyte activation
Furthermore, assessment of lymphocyte activation, using the early lymphocyte
activation marker CD69, in the PopLN showed significant decrease in THC-treated DTH
mice compared to vehicle (Fig. 4.2A). As CD69 can be used as an early activation
marker for both T and B cells we next looked at both CD3+CD69+ T cell and
CD19+CD69+ B cell populations. THC treated DTH mice showed a decrease in both
proportion (Fig. 4.2 B&D) and absolute cell counts (Fig. 4.2 C&E). We next studied
Th17 cells by double-staining for IL-17 and CD4. The gating of such cells revealed that
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IL-17a producing T cells also showed significant decrease in the proportion and absolute
numbers in DTH+THC treated mice compared to DTH+Veh mice (Fig. 4.2 F&G).
THC treatment reduces expression of proinflammatory transcription factors
To show that THC treatment was inhibiting T helper cell driven inflammation we
next looked at proinflammatory cytokines which have been linked to DTH including IL17a/f, IFN-γ, and TNF-α (219). We observed significant decreases in spontaneous
secretion of IL-17, IFN-γ and TNF- in DTH+THC treated mice when compared to
DTH+Veh treated mice (Fig. 4.3A). Having seen a decrease in Th1 and Th17
proinflammatory cytokines, IFN-γ and IL-17a/f respectively, we next looked at lineagedependent transcription factors Tbx21 (Tbet for Th1), and RORγT and IRF4 (for Th17)
in the PopLN cells (220); (221); (222). THC treatment significantly decreased the
expression of both Th1 and Th17 lineage specific transcription factors, compared to
vehicle treated DTH mice, (Fig. 4.3B). Finally, we looked at markers of overall
inflammation including Pten, the PIK3/Akt inhibitor, and NFκB, a transcription factor
critical for expanding proinflammatory cytokine expression (223); (224). Interestingly,
THC treatment of DTH mice caused a significant increase in Pten levels (Fig. 4.3C) and a
correlative drop in NFκB expression (Fig. 4.3D) when compared to DTH+Veh mice,
indicative of a reduced inflammatory response.
Induction of DTH in mice causes miRNA dysregulation
The importance of miRNA in hypersensitivity was recently highlighted by the
observance of similarly elevated miRNA expression in both human and mouse allergic
contact dermatitis skin samples (225). Using Affymetrix miRNA array version 4 (JHMI
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deep sequencing & microarray core) we assessed the expression of over 3,000 miRNA in
the PopLN from naïve and DTH mice. In order to visualize the miRNA dysregulation
caused by DTH a heat map was constructed using log transformation of fluorescent
intensities obtained from the FlashTag biotin HSR hybridization (Fig. 4.4A). One
thousand five hundred and twenty-nine miRs were up/down regulated in DTH mice
compared to naïve; however the expression of only 70 miRNA were altered at greater
than 2.0 fold change, 51 upregulated and 19 downregulated (Fig. 4.4B). miR-21 and 223 were selected from the top upregulated miRNA (Fig. 4.4B) as potential inflammatory
markers associated with DTH response and validated by qPCR (Fig. 4.4C). Also, of
interest, for possible therapeutic targets, were the top downregulated miRs (Fig. 4.4C) of
which miR-29b, -125a, and -142 were selected and validated by qPCR (Fig. 4.4E).
THC treatment reverses DTH mediated miRNA dysregulation
Having validated two upregulated miRs, and three down-regulated miRs as
markers potentially associated with DTH response, we next set out to determine what
impact, if any, THC treatment in DTH mice would have on these miRNA expression.
Interestingly, DTH+THC mice showed a significant reversal of the DTH dysregulated
miRNA (Fig. 4.5 A&B). Thus, THC treatment caused down-regulation of miR-21 and 223 and up-regulation of miR-29b and -142, while having no significant effect on miR125a. Next, we selected 20 miRs, evenly distributed, from the top up- and downregulated miRs and using Ingenuity pathway analysis (IPA) tried to connect these miRs
of interest to Th1 and Th17 differentiation. In this analysis, we were able to identify 2
miRs namely, miR-21 that was downregulated, and miR-29b that was upregulated in
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DTH+THC mice, were connected to the proinflammatory T helper cell activation
pathway (Fig. 4.5C).
THC-mediated regulation of miR-21 and -29b inhibits Th1 and Th17 differentiation
As implicated by the pathway analysis, IFN-γ is a target of miR-29b as indicated
by the miR SVR score (miRWalk- Fig. 4.6A) and alignment (miRNA.org- Fig. 4.6B).
Thus THC-mediated upregulation of miR-29b may have contributed to decreased IFN-γ
induction. Additionally, SMAD7, a negative regulator of TGFβ signaling, is a strong
target of miR-21 as indicated by the miR SVR score (miRWalk- Fig. 4.6A) and
alignment (miRNA.org- Fig. 4.6D) (226). Thus, THC-mediated down-regulation of miR21 may have contributed to increased SMAD7. Next, we tried to confirm the expression
of these molecules in the PopLN cells using qPCR. The data indicated that THC
treatment of DTH mice was able to decrease IFN-γ (Fig. 4.6C) and increase SMAD7
expression in PopLN cells (Fig. 4.6E) when compared to DTH+Veh mice.
THC treatment alters microRNA specific target gene expression
In order to confirm that the reduced proinflammatory T helper cell differentiation
was due to the miRNA regulation, we next looked at primary cell transfections with miR21 and -29b. Draining lymph node cells from DTH mice were transfected (HiPerFectQiagen) with either miRNA mimics or inhibitors (Qiagen) for six hours with target gene
expression assessed at 24 hours after transfection. The transfection was performed as
detailed in our previous publications (212); (87); (227). We found that miR-29b inhibitor
significantly increased IFN-γ levels compared to miR-29b overexpression (Fig. 4.6F).
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Additionally, SMAD7 levels were significantly elevated with miR-21 inhibition
compared to miR-21 overexpression (Fig. 4.6G).
4.4 DISCUSSION
While cannabinoid receptor agonists have been shown to reduce type IV
hypersensitivity associated with DTH the role of THC as an epigenetic regulator of
proinflammatory T helper cell differentiation has not yet been fully elucidated in this
model (217); (218); (83). To this end, we investigated the effect of THC on mBSAinduced DTH response which is mediated primarily by Th17 and Th1 cells, specifically
addressing how THC may downregulate the transcription factors and cytokines that
promote such T cell activation. Furthermore, we also investigated how THC can induce
miR expression so as to alter the expression of some key regulatory pathways that impact
Th17 and Th1 differentiation.
The natural compound THC found in marijuana is well known for its
immunoregulatory properties. Specifically, in regards to T cell activation, THC treatment
has been shown to reduce secretion of proinflammatory cytokines, including IFN- and
TNF-, and suppress proliferation of T cells via apoptosis and/or induction of regulatory
immune cells such as Tregs and MDSCs (79); (84); (76); (86); (154). As such, THC has
been shown to be highly effective therapeutically in numerous models of T cell driven
inflammatory disease including inflammatory lung injury, autoimmune hepatitis, and
allogenic hematopoietic cell transplantation (88); (76); (78). To this end, we studied the
effect of THC on type IV hypersensitivity in mice. This hypersensitivity is involved in
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inducing contact dermatitis against a wide range of antigens such as those found in
poison ivy and metals such as nickel.
DTH as type IV inflammatory reaction against antigens plays a critical role in
protection against infections with intracellular pathogens. However, chronic DTH
response can also trigger significant tissue damage. Moreover, contact with noninfectious antigens such as nickel or poison ivy can also trigger a robust DTH response
leading tissue damage. In such instances, there is need for the use of anti-inflammatory
and immunosuppressive drugs to attenuate T cell activation. Understanding that DTH
response is complicated by the fact that both Th1 and Th17 cell subsets have been shown
to contribute to the overall pathogenesis associated with disease progression is necessary
for developing therapeutics (228). The ability of THC to act as an inhibitor of Th1driven inflammation, which we saw in the current study, has been well documented in
other models such as cancer and autoimmunity (229); (84). However, the role of THC as
a Th17 inhibitor has been more indirect focusing, instead, on THC-mediated Treg
induction as the main modulator of Th17 regulation (76); (88). Nonetheless, in the
current study we show a direct inhibition of Th17 differentiation via a derepression of
SMAD7, a known inhibitor of the Th17 lineage, which occurs upon THC treatment of
DTH mice (226). Although there is no direct evidence to show that THC can inhibit Th1
and Th17 differentiation simultaneously, recently cannabinoid receptor agonists were
shown to reduce concurrent Th1/Th17 cell differentiation (230). This corroborates our
findings that THC treatment of mBSA-induced DTH response reduces the secretion of
Th1/Th17 activating cytokines, IFN- and IL-17a/f, and lineage specific transcription
factors, Tbet and RORgT.
82

Epigenetic modifications, including miRNA expression, have been linked to
fundamental biological processes including, but not limited to, cellular differentiation and
proliferation (225); (231). As such, dysregulation of miRNA seen in disease models,
including psoriasis, multiple sclerosis, and rheumatoid arthritis, has become a topic of
major interest for possible therapeutic targets (232); (233); (234). In the current study,
we identified two miRNA and two target genes as possible therapeutic modalities: miR21 with its target SMAD7 and miR-29b with its target IFN-. miR-21 has been identified
to play a critical role in multiple inflammatory models, including allergic contact
dermatitis, rheumatoid arthritis, and experimental autoimmune encephalomyelitis, for the
regulatory role it plays in Th17 differentiation (225); (235); (226). As suggested by
Vennegaard et al. who saw elevated levels of miR-21 in the skin of mice with allergic
contact dermatitis, we observed greater than 2.0 fold increase in miR-21 expression in
mice with DTH response, when compared to naïve controls. Furthermore, miR-29b has
been shown to be necessary in the regulation of Th1differentiation in mice, and
implicated in various inflammation models (236); (237); (238); (239). We observed a
downregulation of miR-29b greater than 2.0 fold in mice with DTH when compared to
naïve controls, indicating a loss of restriction in the Th1 cell lineage and therefore
promoting their differentiation.
We suggest in this study that the ability of THC to impact T helper cell
differentiation stems from its ability to act as an epigenetic regulator. While only limited
research exists on the role THC plays in the regulation of epigenetic modifications, this
research base is growing. THC treatment has been found to alter DNA methylation
patterns in diseases which elicit inflammatory response such as, simian
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immunodeficiency virus (SIV), and even in regulatory immune cells, including myeloid
derived suppressor cells (MDSC) (129); (214). The role of THC in histone mark
regulation, both acetylation and methylation has only recently been studied by Yang et al.
in T helper cell subsets (38). Additionally, research centered on THC-mediated
alterations of miRNA profiles is severely limited (88); (240); (87). Thus, to more fully
understand what role THC treatment is playing in T helper cell differentiation, we looked
at the ability of THC to alter miRNA expression changes seen due to DTH. Interestingly,
we saw a complete reversal of DTH-induced upregulation of miR-21 and -223 as well as
downregulation of miR-29b, -125a, and -142. Having shown that THC treatment reduced
Th1 and Th17 specific cytokines and transcription factors, we focused in on miR-21 and 29b, and using transfection of primary cells proved direct targeting of SMAD7 and IFN-
messages, respectively.
In conclusion, the current study suggests that the elevated levels of IFN- seen in mice
with DTH potentially caused by an increase in miR-21 expression and subsequent
decrease in SMAD7, may induce increased Th17 differentiation (Fig. 4.7). However,
with THC treatment, miR-29b, an inhibitor of IFN-, was overexpressed indirectly
downregulating miR-21, and thereby derepressing SMAD7 (Fig. 4.7). In short, THC
treatment was able to effectively inhibit Th1 and Th17 lineages in the DTH model of
hypersensitivity. Together these findings suggest that THC can be used therapeutically in
type IV hypersensitivity as well as autoimmune models where Th1 and Th17 cells have
been implicated in disease progression. Furthermore, our findings that THC regulates T
helper cell differentiation via altered miRNA expression are vital to fully elucidating the
role cannabinoid receptor agonists play in adaptive immunity.
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Table 4.I. Primer sequences for qPCR analysis of gene expression in popliteal
lymph node cells.
Gene

Primer

Sequence (5’-3’)

Annealing
Temp

Forward GGC TGT ATT CCC CTC CAT CG
β actin
Reverse

CCA GTT GGT AAC AAT GCC ATG T

Forward AAC CGC TTA TAT GTC CAC CCA
Tbet
Reverse

CTT GTT GTT GGT GAG CTT TAG C

Forward CAA GTT TGG CCG AAT GTC C
RORγT
Reverse

CTA TAG ATG CTG TCT CTG C

Forward GTC TCA CGG GTG CTT TCT GT
IRF4
Reverse

GGC TGG GCA TTC TCA CGA TA
60°C

Forward CCT TTT GAA GAC CAT AAC CCA CC
Pten
Reverse

GAA TTG CTG CAA CAT GAT TGT CA

Forward ATG GCA GAC GAT GAT CCC TAC
NFκB
Reverse

TGT TGA CAG TGG TAT TTC TGG TG

Forward GCG TCA TTG AAT CAC ACC TG
IFN-γ
Reverse

GAG CTC ATT GAA TGC TTG GC

Forward GCA TTC CTC GGA AGT CAA GAG
SMAD7
Reverse

CCA GGG GCC AGA TAA TTC GT
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Figure 4.1: THC treatment reduces lymphocyte driven inflammation associated
with DTH.
Mice (n=5 per experimental group) were sensitized, subcutaneously 1.5mg/mL of mBSA
in CFA. Sensitized mice were treated with THC (20mg/kg) or vehicle, on days 4, 5, and
6 after sensitization. Mice were rechallenged (10mg/mL mBSA) via a foot pad injection
on day 6. Swelling was measured as:
𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑜𝑓 𝑚𝐵𝑆𝐴 𝑓𝑜𝑜𝑡𝑝𝑎𝑑−𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠𝑜𝑓 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑓𝑜𝑜𝑡𝑝𝑎𝑑
𝑇ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 𝑜𝑓 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑓𝑜𝑜𝑡𝑝𝑎𝑑

𝑥100%. (A) Schematic of model and

treatment regimen. (B) Relative percent swelling compared to naïve mouse footpad (for
each hind paw foot pad). (C) Absolute cell count of draining lymph nodes (per mouse).
Lymphocytes from mBSA-sensitized mice were rechallenged with mBSA, 40 mg/mL,
and then cultured for 48 hours. In the last 16 hours of culture, the cells were pulsed with
2µCi of [3H]Thymidine. (D) The cells were harvested and analyzed for Thymidine uptake
using a β-Scintillation counter. Histopathological analysis of mBSA rechallenged (DTH)
footpad. The footpad was then embedded in paraffin and sectioned into 6µm sections
and stained for Hematoxylin and Eosin. Mice were sensitized with mBSA, treated with
either vehicle (E&G) or THC (F&H), and rechallenged with either vehicle (E&F) or
mBSA (G&H). The footpad was isolated and fixed/decalcified in Cal-Rite. Vertical bars
represent Mean+/- SEM. ANOVA/Tukey * p<0.05 ** p<0.01 ***p<0.001
****p>0.0001
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Figure 4.2: THC treatment reduced lymphocyte activation.
DTH-induced mice were treated with THC or vehicle as described in Fig 1 legend. (A)
Absolute cell counts CD69+ lymphocytes (per lymph node). (B) Flow cytometry
histograms showing CD3+CD69+ T cells and (C) absolute cell counts (per lymph node).
(D) Flow cytometry histograms showing CD19+CD69+ B cells and (E) absolute cell
counts (per lymph node). Cells from the LN were cultured for 4 hours in the presence of
PMA, Ionomycin, and Golgi Plug and stained for IL-17a secreting cells. (F) Flow
cytometry histograms showing CD4+IL17+ T cells and (G) absolute cell counts (per
lymph node).Vertical bars represent Mean+/- SEM. ANOVA/Tukey * p<0.05 **
p<0.01 ***p<0.001 ****p>0.0001
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Figure 4.3: THC treatment reduces inflammatory cytokines and transcription
factors.
DTH-induced mice were treated with THC or vehicle as described in Fig 1 legend. Cells,
mBSA-sensitized in vivo, were cultured overnight without mBSA to analyze spontaneous
cytokine secretion. (A) Culture supernatants were analyzed for pro-inflammatory
cytokines IL-17, IFN-γ, and TNF-α via ELISA MAX kit (Biolegend). (B-D) cDNA was
isolated from the PopLN of and analyzed using qPCR. (B) Analysis of pro-inflammatory
T cell transcription factors Tbet, RORγT, and IRF4, (C) Analysis for PIK3/Akt regulator
Pten, and (D) Analysis of transcription factor NFκB. Vertical bars represent Mean+/SEM. Student’s t test * p<0.05 ** p<0.01 ***p<0.001 ****p>0.0001
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Figure 4.4: DTH reaction causes changes to microRNA expression in immune cells.
Lymphocytes from popliteal lymph nodes (PopLN) of naïve and DTH mice were
assessed for miR expression. (A) Heat map highlighting the microRNA dysregulation
between naïve and DTH samples (n=5 per experimental group). (B) Venn diagram
depicting the up and down regulated microRNA (greater than 2 fold). (C) IPA ingenuity
analysis of top up and down regulated microRNA. (D-E) qPCR validation of
microRNAs of interest (D) miR-21-5p and miR-223-3p (E) miR-29b-3p, miR-125a-5p,
and miR-142-5p. Vertical bars represent Mean+/- SEM. Student’s t test * p<0.05 **
p<0.01 ***p<0.001 ****p>0.0001
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Figure 4.5: THC treatment reverses DTH-mediated alterations in microRNA
expression.
DTH-induced mice were treated with THC or vehicle as described in Fig 1 legend. (A-B)
cDNA was isolated from DTH+Veh and DTH+THC PopLN for validation of microRNA
array using q-PCR (A) Analysis of miR-21-5p and miR-223-3p (B) Analysis of miR-29b3p, miR-125a-5p, and miR-142-5p. (C) IPA ingenuity software was used to determine
interactions between miR-21-5p and miR29b-3p and the pro-inflammatory T cell
pathway. Vertical bars represent Mean+/- SEM. Student’s t test * p<0.05 ** p<0.01
***p<0.001 ****p>0.0001
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Figure 4.6: THC treatment alters microRNA-specific target gene expression.
DTH-induced mice were treated with THC or vehicle as described in Fig 1 legend. cDNA
and protein was isolated from DTH+Veh and DTH+THC PopLN for validation of target
gene message using q-PCR. (A) Predicted or experimentally observed miRNA target
genes (TargetScan and miRWalk). (B and D) Schematic illustration of differentially
regulated miRNA (B) miR-29b and (D) miR-21 targeting the 3’-UTR of potential target
genes (microRNA.org). (C and E) q-PCR validation of microRNA target gene message
(C) IFN-γ and (D) SMAD7. Draining lymph nodes, from DTH mice, were transfected for
6 hours and then cultured overnight (18 hours). (E-F) Validation of pro-inflammatory T
cell gene targets (E) IFN-γ and (F) SMAD7. Vertical bars represent Mean+/- SEM.
Student’s t test or ANOVA/Tukey * p<0.05 ** p<0.01 ***p<0.001
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Figure 4.7: Schematic of the role microRNA plays in mBSA induced DTH.
mBSA induced DTH is classically associated with elevated Th1 and Th17 response, and
increased expression of miR-21. Th17 differentiation is increased via miR-21 inhibition
of SMAD7. THC treatment of DTH mice causes a decrease in the proinflammatory
response through microRNA regulation, increasing expression of miR-29b (inhibitory of
IFN-γ) and decreasing miR-21 expression. Thus THC treatment reduces IFN-γ
production and inhibition of IL-17 regulation via SMAD7 derepression.
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CHAPTER V: Endocannabinoid 2-arachidonyl glycerol inhibits inflammation associated
with delayed type hypersensitivity via reduced T cell response
5.1 INTRODUCTION
The endocannabinoid (EC) system consists of cannabinoid (CB) receptors (CB1
and CB2) as well as the endogenous ligands for these receptors, called endocannabinoids
(EC) (3). Anandamide (AEA) and 2-arachidonyl glycerol (2-AG) the first discovered
ECs remain the most widely studied to this day (23); (24). 2-AG has been proposed as
the "true natural ligand" for CB receptors for three main reasons: multiple synthesis
pathways, elevated tissue expression, and agonist activity at both CB receptors (241). 2AG can be formed along a degredative pathway from inositol phospholipid hydrolysis via
multiple phospholipases (PL) and diacylglycerol lipase (31); (32). Additionally, 2-AG
can be synthesized from arachidonic acid-containing phosphatidylcholine via variable PL
and phosphatidic acid phosphatase (31). Increased pathways for biosynthesis explains
why, unlike AEA which is only present at high levels in the brain and uterus, 2-AG is
well expressed in numerous tissues (242); (243); (23); (244); (245); (246). Furthermore,
2-AG exhibits both binding affinity and efficacy for CB1 and CB2 receptors making it a
full agonist for the CB receptors (247).
The notion that the EC system plays a role in immune response has long been
apparent, with CB2 constitutively expressed on immune cells and the expression of CB1
upregulated upon activation in T cells (13). Type IV hypersensitivity (delayed type
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hypersensitivity, DTH) is driven by proinflammatory T helper cell subsets, Th1 and Th17
that produce IFN-γ and IL-17 respectively (69); (52); (248). Moreover, a study using
2,4-dinitroflurobenzene to induce ear dermatitis found increased ear weight to correlate
with elevated 2-AG levels (249). Also, mice deficient in CB receptors were found to
exhibit increased response to contact hypersensitivity (217). In contrast, mice lacking
Fatty Acid Amide Hydrolase (FAAH) that express heightened anandamide levels showed
decreased response to contact hypersensitivity (217). These data clearly suggested a role
for endocannabinoids in suppressing the DTH response in vivo. Nonetheless, there is
also evidence to suggest that endocannabinoid levels increase during inflammation or
autoimmune disease, a finding that has been used to indicate that endocannabinoids may
in fact promote inflammation (217).
There are no studies that have measured the levels of endocannabinoids in
immune cells during naïve and activation stage and tried to correlate that with the levels
found during an ongoing immune response. In the current study, we investigated the
levels of ECs, particularly 2-AG in naïve and activated T and B cells using mBSA as an
antigen which triggers not only DTH response mediated by Th1 and Th17 cells but also
B cells to produce antibodies. The data suggest that 2-AG is produced at higher levels
upon T and B cell activation and systemically during the DTH response but that 2-AG
plays a regulatory role in trying suppress inflammation rather than promote it.
Here we demonstrate that exogenous treatment with 2-AG can reduce
inflammation seen in DTH via inhibition of T cell activation and proliferation.
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5.2 MATERIALS AND METHODS
MiceFemale C57BL/6 (BL6) mice, aged 6-8 weeks and at an average weight of 20 g, were
obtained from Jackson Laboratories and used as naïve controls in each experiment. All
mice were housed in pathogen-free conditions and allowed ad libitum access to filtered
water and Teklad rodent diet 8604 (normal chow) at the Animal Research Facility located
at the University of South Carolina School of Medicine. All experiments were conducted
under an approved Institutional Animal Care and Use Committee animal protocol.
T and B cell isolationSingle cell suspension from the spleens of BL6 mice was plated for 1 hour at 37°C, for
removal of adherent cells. Cells in suspension were gently aspirated and resuspended in
complete RPMI media (1% v/v penicillin/streptomycin, 1% v/v HEPES buffer, 10% v/v
heat inactivated FBS, and 0.0002% v/v 2-mercaptoethanol). Nylon wool column, wetted
with complete media, was then loaded with single cell suspension and incubated 1 hour at
37°C. T cells were isolated based on nonadherence as elute and wash from nylon wool
column (250). B cells adhering to the nylon wool were isolated by compression of
incubated nylon wool, using sterile syringe plunger and complete medium. Purity
(greater than 90%) was checked using flow cytometer.
Endocannabinoid extractionBriefly, endocannabinoids were extracted from sample with internal standards
(deuterated endocannabinoids (Cayman Chemical) AEA-d4 (10ng/mL), 2-AG-d5
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(20ng/mL), and PEA-d4 (200ng/mL) diluted in 50:50 (methanol:water) and
(phenylmethylsulfonyl fluoride) PMSF in acetonitrile. Samples were diluted in 0.1333%
TFA ultra purified water, to 20% (v/v) acetonitrile, and ultracentrifugation used to
separate out cellular debris. Samples are then cleaned using SPE columns (Bond Elute
C8). Briefly, ultracentrifugation supernatant was loaded onto the activated SPE column,
the elute was discarded, and then the column was cleaned using 20% acetonitrile, the
elute was discarded. The endocannabinoids were eluted using 80% (v/v) acetonitrile in
0.1333% TFA ultra purified water and evaporated to dryness. All samples were stored at
-80°C.
Liquid chromatography/Tandem Mass spectrometery -(LC/MS/MS)Sample, resuspended in 100uL 80% (v/v) acetonitrile, was injected in a volume of 10 µL
on to a C18 reverse phase analytical column (particle size 5 µm 2.1 x 150 mm ES
Industries #06601-12-54-45318). Endocannabinoids were eluted using a linear binary
gradient flowing at 200 µL/min on a Waters Acquity HPLC system. The gradient solvent
composition began at 50% A: 50% B (solvent A: water/acetonitrile (95:5) with 1%
ammonium acetate and 0.1% formic acid; solvent B: methanol with 1% ammonium
acetate and 0.1% formic acid ) and increased to 0%A: 100%B over 28 minutes. The
Mass spectrometer (Waters Premier XE triple quadrupole) was operated in multiple
reaction monitoring (MRM) mode using positive ion electrospray ionization. The
electrospray probe was held at 3 kV.Optimized mass spectrometer operating parameters
for quadrupole mass spectrometer with electrospray ionization source in tandem with
liquid chromatography (Micromass Quattro-LC, Waters) are listed in Table I. Waters
Masslynx software was used for analysis.
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Induction of delayed type hypersensitivity (DTH) and 2-AG treatmentDTH was induced in C57BL/6 mice using a sensitization/rechallenge method (Jackson et
al 2014 (83)). Briefly, mice were sensitized with a subcutaneous injection (100 µL/hind
flank) of 1.5 mg/mL methylated BSA (mBSA- Sigma Aldrich) emulsified in complete
Freunds adjuvant (CFA- Sigma Aldrich). Six days later, the mice were rechallenged with
footpad injection (20 µL/footpad) of 10 mg/mL mBSA in 1xPBS. 2-Arachidonoyl
glycerol (2-AG- Cayman Chemical) evaporated under a stream of nitrogen was dissolved
in ethanol (20mg/mL) and then diluted in 1xPBS to a concentration and used in mice at a
concentration of 40mg/kg. 2-AG or vehicle (ethanol diluted in 1xPBS) was administered
intraperitoneally (i.p.) at a volume of 0.1 mL/mouse into DTH mice daily Day 4 - Day 6.
Percent swelling was measured as [(Thickness(mBSA rechallenged footpad) Thickness(1xPBS rechallenged footpad)) / Thickness(1xPBS rechallenged footpad)] *
100.
Monoclonal antibodies, reagents, and flow cytometerAntibodies used for flow cytometric analysis (BioLegend) included: FC block (93), antiCD3 (145-2C11), anti-CD19 (6D5), and anti-CD69 (H1.2F3). Popliteal lymph node cells
(PopLN- 106 cells) from DTH BL6 mice were incubated with FC receptor antibodies (10
min) and incubated with conjugated antibodies (20-30 minutes at 4°C). After incubation,
with conjugated antibodies, cells were washed twice with 1xPBS/2% fetal bovine serum
buffer. The stained cells were then assessed by flow cytometer (FC500; Beckman
Coulter) and the resulting data analyzed by Cytomics CXP software (Beckman Coulter).
Three-color flow cytometric analysis was used to profile the lymphocyte activation.
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Cytokine analysis in cell culture supernatantsELISA MAX sandwich enzyme-linked immunosorbent assay (ELISA) kits (BioLegend)
were used to assess the levels of IL-2, IL-6, IL-17a/f, IFN-γ, and TNF-α cytokines. Cells
were isolated from spleen and draining lymph nodes of DTH mice, plated at 0.8x106
cells/well, cultured 24 hours for cytokine secretion in complete RPMI media (1% v/v
penicillin/streptomycin, 1% v/v HEPES buffer, 10% v/v heat inactivated FBS, and
0.0002% v/v 2-mercaptoethanol) with phorbol 12-myristate 13-acetate (PMA) and
calcium ionophore ionomycin (50 ng/mL and 10 μg/mL respectively). Cytokine
production was quantified from cell supernatants (stored at -20°C). Plasma was assessed
for IgG levels using sandwich ELISA (Abcam). Absorbance was measured at 450 nm
using a Victor2 1420 Multilable counter (Wallac).
Cell proliferation assaysSpleen cells from naïve mice were co-cultured in triplicate (0.2 mL/well in a round
bottom 96 well plate) with ConA (2.5µg/mL) or LPS (5µg/mL) to stimulate T and B cell
proliferation, respectively. Splenocytes from DTH mice rechallenged in vivo were
assessed for spontaneous proliferation. In some experiments, 2-AG was added at the
time of cell seeding at increasing doses (0.9, 1.9, and 2.9 µM). Sixteen hours before
collection and analysis, [3H]thymidine (2 µCi/well) was added to the cell cultures.
Radioactivity was measured using a liquid scintillation counter (MicroBeta Trilux).
Statistical analysisData were shown as mean ± S.D. Student’s t-test was used to compare data between two
groups. One-way ANOVA with Tukey post-hoc test was used to compare three or more
98

groups. Experimental groups were compared to controls, and p < 0.05 was considered
significant.
5.3 RESULTS
Basal levels of the endocannabinoid, 2-AG increases in lymphocytes upon activation
While endocannabinoid levels have been previously measured in secondary
lymphoid organs (245, 246), to the best of our knowledge, the levels in various immune
cells during naïve and activation stages have yet to be determined. As such, we isolated
naive T and B cells from BL6 mouse spleens, and using LC/MS/MS, quantified basal
levels of AEA and 2-AG in these cells (Fig. 5.1A). We found that AEA levels, while
detectable were minimal and were significantly lower than 2-AG in both T and B cells
(Fig. 5.1B). For this reason, we focused our studies only on 2-AG. In order to quantify
changes in 2-AG expression/secretion in activated T and B cells, we activated
splenocytes with the mitogens Concanavalin A (ConA) or the endotoxin
lipopolysaccharide (LPS), which activate polyclonally, T and B cells respectively, and
measured the levels of enocannabinoids within the cells as well as in the culture
supernatants. Upon activation, significantly higher levels of 2-AG were found in
activated T and B cell supernatants than in the activated cells themselves (Fig. 5.1C-D).
Moreover, activated B cell culture supernatants had much higher levels of 2-AG than
supernatants from activated T cell cultures.
To ensure that the elevated endocannabinoid levels were biologically relevant, we
used methylated bovine serum albumin (mBSA) to induce DTH hypersensitivity, which
is associated with proinflammatory T cell response (69); (52); (248). The DTH response
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following injection of mBSA into footpads led to significant swelling in the hind
footpads of mice (Fig. 5.1E) as well as increased cellularity in the draining popliteal
lymph nodes (PopLN) (Fig. 5.1F). Interestingly, when we measured 2-Ag levels in the
plasma of the DTH mice, we saw a significant increase in 2-AG levels when compared to
naïve mice (Fig. 5.1G), AEA levels remained low although detectable (data not shown).
To confirm that the PopLN cells were actually getting activated, we analyzed them for
activation markers such as CD69, which was significantly enhanced in mBSA injected T
and B cells (Fig. 5.1 H&I).
2-AG treatment reduces inflammation associated with DTH
Because cannabinoids are immunosuppressive, the increase in endocannabinoids
following activation of immune cells suggested a negative feedback loop aimed
controlling the hypersensitivity response. To that end, we tested if exogenous treatment
with this endocannabinoid could inhibit inflammation in higher concentrations would
suppress DTH response. As such, DTH mice were treated with 2-AG (40mg/kg i.p.)
once daily on days 4-6 (Fig. 5.2A). Interestingly, we found that 2-AG treatment was able
to significantly decrease footpad swelling (Fig. 5.2B). Also, the total number of activated
T cells (CD3+CD69+) and B cells (CD19+CD69+) in the PopLN were significantly
decreased in 2-AG treated mice compared to vehicle controls (Fig. 5.2 C). In order to
more fully elucidate how 2-AG was reducing the mBSA induced hypersensitivity we next
looked at spontaneous cytokine secretion of PopLN cells of DTH mice. We assessed
classical Th17 and Th1 proinflammtory cytokines triggered by mBSA antigen during the
DTH response. Cytokines associated with Th17 activation, IL-17a/f (Fig. 5.2E), and
differentiation, IL-6 (Fig. 5.2H), were significantly decreased in DTH+2-AG treated mice
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compared to DTH+Veh mice. Furthermore, Th1 secreted cytokines including IFN-γ (Fig.
5.2F) and TNF-α (Fig. 5.2G) were also significantly reduced in DTH+2-AG mice,
compared to controls. Additionally, we saw IL-2 levels significantly decrease with 2-AG
treatment indicative of reduced T cell activation and proliferation in the draining lymph
nodes (Fig 5.2I). Because mBSA, can also trigger Ab response (248), we measured IgG
levels in the plasma and found that treatment with 2-AG caused significant decrease in
IgG levels when compared to vehicle controls (Fig. 5.2J)
2-AG modulates DTH disease parameters via inhibition of T cell proliferation
We next determined if 2-AG acts directly on T and B cells. To that end, we
cultured the PopLN cells from mBSA immunized mice in the presence of 2-AG or
vehicle. We observed a dose- dependent suppression of spontaneous lymphocyte
proliferation of antigen-activated cells as well as Con-A activated T cells and LPS
activated B cells in the presence of 2-AG when compared to vehicle controls (Fig. 5.2KM). These data suggested that 2-AG was acting directly on activated T and B cells to
suppress lymphocyte activation and proliferation.
5.4 DISCUSSION
Recently, we hypothesized that endocannabinoids may play a critical role in the
regulation of inflammation associated with autoimmune diseases (251). Our laboratory
and others have found that exogenous treatment of autoimmune inflammation with AEA
can attenuate inflammatory disease (252); (253); (76); (254); (83). However, research on
2-AG in inflammatory models is mostly limited to increasing basal levels via inhibition
of the 2-AG degredative enzyme, MAGL (255); (256). One exception being a study
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which found that exogenous 2-AG increased the neuroprotection and decreased the
mortality in mice bearing experimental autoimmune encephalomyelitis (257). However,
there are no studies that have investigated the levels of 2-AG in naïve and activated
immune cells and correlated that with inflammation. As such, we set out to test the levels
of endocannabinoids during inflammation. We chose mBSA as an antigen because it
triggers DTH reaction that can be measure clinically as footpad swelling as well as lymph
node activation. In addition, this antigen has been shown to activate not only both Th1
and Th17 cells but also antibodies (258); (83).
The EC system has been associated with immune response due to the fact that
cannabinoid receptors are expressed on immune cells and that measurable EC levels have
been detected in secondary immune organs (246); (245). Our findings show that basal
levels of AEA and 2-AG can also be found in naive T and B cells. Traditionally
endocannabinoids are considered to be synthesized as needed, from the lipid membranes,
rather than stored (28). However, EC binding of the cannabinoid receptors has been
associated with release of signal molecules such as ceramide, a bioactive lipid, which
regulates cellular differentiation, proliferation, and apoptosis (74). This suggests that
basal levels of endocannabinoids may be necessary for regulation of basic cell function.
Furthermore, we found that 2-AG levels were significantly elevated in cell supernatants
of activated T and B cells, and in the plasma of DTH mice. These findings suggest that
2-AG may be synthesized upon activation by T and B cells, and are consistent with other
studies demonstrating elevated systemic 2-AG levels in various disease models
associated with inflammation, including hepatic ischemia-reperfusion injury, obesity, and
post-traumatic stress disorder (259); (260); (261).
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While Mimura et al. recently observed that 2-AG levels correlated with ear
weight gain, due to dermatitis, in a CB2 dependent manner (249), we found that not only
does the 2-AG levels increase during DT H in vivo but also, exogenous administration of
2-AG was able to suppress the inflammation associated with the DTH response.
Exogenous 2-AG has been shown to inhibit the proliferation of T cells, in vitro, to antiCD3 mAb stimulation (89). Furthermore, activated Jurkat T cell, as well as primary
splenocyte secretion of IL-2 was suppressed in vitro upon co-culture with 2-AG (90);
(91). The role of 2-AG in regards to B cells is more complicated due to the fact that 2AG, at nM concentrations, can stimulate chemotaxis and chemokinesis in
B220+CD19+IgD+IgM+ spleen cells via CB2 receptor binding (262). However, in LPS
activation of B cells, in vitro, 2-AG caused decreased proliferation at µM concentrations
(89). This evidence supports our claim that exogenous 2-AG treatment can be inhibitory
to inflammation associated with type IV hypersensitivity.
The conflicting data surrounding the effect of 2-AG on immune regulation
suggests that 2-AG concentration is vital for eliciting an anti-inflammatory response.
Our findings highlight the concept that anti-inflammatory properties of 2-AG are dose or
threshold-dependent as shown in our proliferation studies. We observed that 2-AG at the
lowest dose caused minor or nonsignificant (NS) suppression of lymphocyte proliferation
while higher doses ablated DTH and ConA induced T cell proliferation. It should also be
noted that in vivo, 2-AG levels are regulated by a serine hydrolase, monoacylglycerol
lipase (MAGL), which is the main enzyme responsible for inactivating 2-AG in vivo
(256). This may account for the fact that to induce significant anti-inflammatory effects,
it is necessary to administer higher concentrations of exogenous 2-AG.
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Together, the current study suggested that endocannabinoids such as 2-AG may
play a critical role in the regulation of immune response. Also, treatment with 2-AG can
be used to decrease T and B cell-dependent immune response. The use of 2-AG to
suppress DTH may be useful to against contact dermatitis. Additionally, these findings
also suggest that 2-AG can be used therapeutically to treat various models of Th1 or
Th17 driven inflammation, as seen in a number of autoimmune diseases.
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Table 5.I. Optimized MRM tuning parameters.

AEA
AEA-d4
2-AG
2-AG-d5
O-AEA

MRM
Transitions
348 > 62
352 > 66
396 > 379
401 > 384
348 > 62

Cone Voltage
(V)
30
30
15
15
30

Collision
Energies (eV)
18
18
20
20
18

304 > 62

30

18

(loading control)

PEA-d4
(extraction control)

105

Dwell
(sec)

60

Figure 5.1: Lymphocyte activation both in vitro and in vivo causes dysregulation of
endocannabinoid levels.
T and B cells isolated from naïve C57BL/6 spleens (n=2) using nylon wool column
separation after adherent cell exclusion (purity determined using anti-CD3 and anti-CD19
labels by flow cytometry. (A) Raw chromatogram for naïve T and B cells after
LC/MS/MS detection. (B) Quantified AEA and 2-AG levels in naive lymphocytes. (CD) Spleens were collected from naïve C57BL/6 mice (n=4) and activated with ConA
(2.5µg/mL) or LPS (5µg/mL) then plated at a density of 1.5x106/mL. Endocannabinoid
2-AG levels quantified, after (C) ConA activation and (D) LPS activation using
LC/MS/MS detection. Delayed type hypersensitivity (DTH) induction, 24 hours after
rechallenge, was determined using disease parameters including footpad swelling and
lymphocyte activation. Plasma was collected and assessed for EC levels (n=5 per
treatment group). (E) Relative percent swelling compared to naïve mouse footpad (for
each hind paw foot pad). (F) Popliteal lymph node absolute cell counts (per mouse). (G)
Circulating 2-AG levels in plasma. (H-I) Absolute cell counts (H) CD3+CD69+ activated
T cells and (I) CD19+CD69+ activated B cells. Representative data from replicate
experiments; Student’s T test or ANOVA/Tukey * p<0.05 ** p<0.01 ***p<0.001
****p>0.0001
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Figure 5.2: Endocannabinoid 2-AG reduces lymphocyte driven inflammation.
2-AG treatment (40 mg/kg) or vehicle (ethanol diluted in 1xPBS) was given on days 4-6
after sensitization. Disease parameters, as described previously, were assessed (n=4 per
treatment group). (A) Schematic of model and treatment regimen. (B) Relative percent
swelling compared to naïve mouse footpad. (C-D) Absolute cell counts (C) CD3+CD69+
T cell activation and (D) CD19+CD69+ B cell activation. Cytokine secretion was
assessed by plating splenocytes with PMA and Ca Ionomycin. (E-I) Secreted levels of (E)
IL-17a/f, (F) IFN-γ, (G) TNF-α, (H) IL-6, and (I) IL-2. (J) Plasma collected 24 hours after
mBSA rechallenge and assessed for IgG levels. (K-M) Splenocytes were stimulated with
(K) mBSA rechallenge (10 mg/mL in vivo), (L) ConA (2.5ug/mL), or (M) LPS
(5.0ug/mL), treated with 2-AG, and co-cultured with 2uCi of [3H]thymidine to assess
proliferation. Representative data from replicate experiments; Student’s T test or
ANOVA/Tukey * p<0.05 ** p<0.01 ***p<0.001 ****p<0.0001
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CHAPTER VI: SUMMARY AND CONCLUSION
In the current study, we examined the ability of THC to act as a regulator of
epigenetic modifications. We first focused on immuneregulatory MDSCs. While there
have been studies showing that THC treatment can alter miRNA expression in MDSCs,
no studies have determined the impact of DNA methylation in these cells (87). We found
that while global methylation patterns, when compared to naïve bone marrow resident
MDSCs, were not significantly altered in THC-induced MDSCs, methylation at specific
loci was. Specifically, methylation was decreased for Arg1 and STAT3 in THC-induced
MDSCs indicative of increased suppressive function.
Next, we looked at the impact of THC on epigenetic modifications in T cells.
While research on THC-mediated epigenetic modifications in T cells is severely limited
what does exist has focused on inhibition of classical, Th1, inflammation (88); (240);
(38). As such, we assessed THC-mediated miRNA regulation in the draining lymph
nodes of DTH mice which exhibit both Th1 and Th17 proinflammatory signals (69); (52).
We found that miRNA dysregulation due to type IV hypersensitivity was regulated back
to naive levels with THC treatment. In particular, miRNAs associated with
inflammation, such as miR-21, were decreased, and anti-inflammatory miRNAs,
including miR-29b, were overexpressed in THC treated DTH mice.
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It has been shown that THC can inhibit Th1 driven inflammation, however its
ability to attenuate transplant rejection, a well-established model of Th1 inflammation,
has not been elucidated (158). We found that THC treatment significantly reduced Th1
proinflammatory cytokines, including IFN-γ and TNF-α. Furthermore, THC treatment
increased survival of both cellular and full thickness skin allogenic grafts in a CB1
dependent manner. We determined that CB1 receptor activation by THC resulted in the
mobilization highly immune suppressive of MDSCs. Interestingly, THC induction of
MDSCs proved necessary for continued allograft survival in our model of HvGD.
The ability of THC to regulate Th17 response has been correlative focusing on
THC-mediated Treg induction rather than direct Th17 inhibition (76); (88). As such, we
used a type IV hypersensitivity model, which is representative of non-classical Th1/Th17
driven inflammation, to determine if THC can directly inhibit Th17 lineage
differentiation. Interestingly, we found that associated cytokines, lineage specific
transcription factors, and absolute numbers of Th1 and Th7 subsets were significantly
reduced in DTH+THC mice compared to DTH+Veh mice. We showed a direct link
between THC treatment and regulation of both Th1 and Th17 differentiation via miRNA
regulation. Specifically, THC treatment of DTH mice increased IFN-γ targeting miRNA
miR-29b, halting Th1 response. Concurrently, THC treatment reduced miR-21
expression freeing SMAD7, a regulator of TGFβ mediated TH17 differentiation.
The literature shows that endocannabinoids, the endogenous ligands for the
cannabinoid receptors, are often elevated in inflammatory models including
autoimmunity and hypersensitivity (263); (264); (259); (260); (261); (249). This
evidence in the past was associated with the endocannabinoids exacerbating
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inflammation, in particular 2-AG. However, this ideology conflicted with the wealth of
data surrounding the exogenous cannabinoid THC. To this end we used exogenous 2AG, a full agonist for both CB1 and CB2 receptors, therapeutically in a DTH model. We
found that 2-AG, like THC a partial agonist at CB1 and CB2 receptors, reduced
inflammation associated with type IV hypersensitivity. Specifically, we observed that
exogenous treatment with 2-AG reduced lymphocyte activation, the secretion of
proinflammatory cytokines, and proliferation. Furthermore, we found that the antiinflammatory properties seen in DTH were closely mirrored in ConA T cell stimulation.
Together, these data suggested that 2-AG was inhibiting hypersensitivity in a T cell
specific manner.
The current findings suggest that cannabinoids can inhibit a wide range of
inflammatory pathways. Additionally, the therapeutic use of CB receptor agonists seem
to be particularly useful as an anti-inflammatory treatment due to the ability of the
cannabinoid to attenuate inflammation via multiple pathways. Specifically, we have
shown that THC inhibits Th1 and/or Th17 driven inflammation through epigenetic
modulation, regulation of T helper cell differentiation, and induction of T cell suppressive
MDSCs. We have further highlighted the importance of the EC system in
immunoregulation through the therapeutic use of 2-AG in DTH. Taken together, our
findings suggest that cannabinoid system plays a critical role in the regulation of
inflammation, thereby offering unique targeting opportunities to treat a wide array of
clinical disorders associated with chronic inflammation.
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